Apobec1-Mediated RNA Editing in Monocytes Contributes to Genetic Heterogeneity and Modulates Monocyte Activity and Development by Estrada, Violeta Rayón
Rockefeller University
Digital Commons @ RU
Student Theses and Dissertations
2017
Apobec1-Mediated RNA Editing in Monocytes
Contributes to Genetic Heterogeneity and
Modulates Monocyte Activity and Development
Violeta Rayón Estrada
Follow this and additional works at: http://digitalcommons.rockefeller.edu/
student_theses_and_dissertations
Part of the Life Sciences Commons
This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and
Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact mcsweej@mail.rockefeller.edu.
Recommended Citation
Estrada, Violeta Rayón, "Apobec1-Mediated RNA Editing in Monocytes Contributes to Genetic Heterogeneity and Modulates
Monocyte Activity and Development" (2017). Student Theses and Dissertations. 393.
http://digitalcommons.rockefeller.edu/student_theses_and_dissertations/393
APOBEC1-MEDIATED RNA EDITING IN MONOCYTES CONTRIBUTES TO 
GENETIC HETEROGENEITY AND MODULATES MONOCYTE ACTIVITY AND 
DEVELOPMENT 
A Thesis Presented to the Faculty of 
The Rockefeller University 
in Partial Fulfillment of the Requirements for  
the degree of Doctor of  Philosophy 
by	
Violeta Rayón Estrada	
June 2017 
ii	
© Copyright by Violeta Rayón Estrada 2017	
APOBEC1-MEDIATED RNA EDITING IN MONOCYTES CONTRIBUTES TO 
GENETIC HETEROGENEITY AND MODULATES MONOCYTE ACTIVITY AND 
DEVELOPMENT 
Violeta Rayón Estrada, Ph.D. 
The Rockefeller University 2017	
Post-transcriptional modifications such as alternative splicing have been shown to 
add to the complexity needed to compensate for the relatively low number of genes found 
in higher organisms. Many other modifications recently found in mRNA, which cannot 
be deduced from what is coded in the genome, such a cytidine to uridine and adenosine to 
inosine editing, reveal that this complexity is ever expanding. Therefore, the current 
challenge is to understand what is the function of these modifications. In this thesis, I 
focus on APOBEC1-mediated RNA editing. 
In higher eukaryotes RNA editing consists of C to U and A to I transitions 
mediated by the proteins of the APOBEC1 and ADAR families, respectively. APOBEC1 
has been fully characterized in its role of editing the Apolipoprotein B (ApoB) transcript 
in the intestine, where the C to U modification changes a glutamate codon to a stop 
codon, creating a smaller version of the ApoB protein. Editing of ApoB is essential for 
the formation of the chylomicron, a lipid transport protein, making APOBEC1 a crucial 
enzyme for lipid metabolism. 
In recent years, our laboratory developed a comparative approach that uses an 
Apobec1-deficient mouse in order to find true Apobec1-mediated editing events in 
wildtype mRNA. This method allowed for the discovery of additional sites in a 
transcriptome-wide manner. Using this, we were able to identify hundreds of additional 
edited sites in murine intestine and macrophages. This opens up the possibility of 
alternative APOBEC1 functions. In this thesis, I focus on the edited sites within 
macrophages, where Apolipoprotein B is not expressed and therefore, where APOBEC1 
may play an alternative role to lipid metabolism. Specifically, these consist of 410 high-
confidence C to U editing events contained in 275 transcripts, the large majority of which 
are within the 3'UTR. 
First, finding that there are no transcriptional differences between macrophages 
derived from Apobec1-deficient and wildtype mice, I characterized the fate of these 
transcripts at the molecular level. Previously, ADAR editing has been shown to 
potentially regulate transcript abundance by nuclear retention and stabilization. Here I 
demonstrated that this is not the case for APOBEC1. However, even though at the RNA 
level, there seem to be no alterations due to editing, I showed that editing does regulate 
translation of protein products, some of which are miRNA mediated. 
The changes observed at the protein level are nevertheless quite small, which is to 
be expected from the low frequency of editing per transcript.  However, a very long-
standing question in the field is whether this is the reflection of a few cells within the 
population that possess 100% editing per site or whether each cell has low frequency 
editing. In order to test for this, we created a statistical model that tested the variability of 
editing at each site among many cells of the same population. Using this model, we 
observed that cells are indeed quite variable in terms of editing. Then I validated the 
results of the model using barcodes that identify individual RNA molecules to amplify a 
region surrounding the edited sites in single cells. Altogether, these experiments 
demonstrated that within the population, cells that are seemingly transcriptionally 
identical are indeed heterogeneous. 
Next, I tested whether the loss of this variability might affect the activity of 
macrophages. To do this, I designed in vitro and in vivo assays. I demonstrated that 
Apobec1-deficient macrophages have altered migration and phagocytosis phenotypes in 
vitro. This predicts that the physiology of monocytes in the Apobec1-deficient mouse 
would be altered. While setting up a competitive reconstitution in vivo assay, where I 
would be able to test wildtype and Apobec1-deficient monocytes side by side, I 
discovered that the development of monocytes is not equivalent between the two 
genotypes. Surprisingly, Apobec1-deficient monocytic progenitors tend to outcompete 
their wildtype counterparts and monocytes have an increased preference to form a pro-
inflammatory Ly6C positive phenotype. Finally, I present a possible link between loss of 
Apobec1 and brain disorders. 
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CHAPTER 1. INTRODUCTION 
The processing of messenger RNA leads to the diversification of the genes in the 
genome by creating alternative proteins though processes such as alternative splicing, 
alternative initiation and termination, frame shifts etc. However, all of these 
modifications are variations of what is encoded in the genome. In this chapter I will 
survey other types of post-transcriptional processing that cannot be deduced from what is 
coded in the genome. Then I will focus on RNA editing, which is a process that directly 
recodes the message through adenosine to inosine and cytidine to uracil nucleoside 
transitions. I will show that these types of modifications have been demonstrated to have 
big biological implications. Finally, I will survey of the state of apolipoprotein B mRNA 
editing catalytic polypeptide 1 (APOBEC1) research at the moment I began my studies 
and will present some preliminary studies performed in my laboratory. 
1.1. Post-transcriptional modifications 
The post-transcriptional modification of RNA is a naturally occurring process that 
occurs during the maturation of RNAs. Today, more than 100 distinct ribonucleoside 
modifications are known and have been shown to be present in all three phylogenetic 
domains: archaea, bacteria and eukarya1. These modifications are most abundant in non-
coding RNA (ncRNA), where they are crucial for properly aiding in translation and 
splicing1.  
Transfer RNA (tRNA) modification is a good example where modifications play 
a very important role in its structure and function. tRNA is both the most highly modified 
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(with 25% of its nucleosides altered) and the one with the most complex chemical 
variety1. For example, different combinations of modifications provide plasticity so that 
tRNA can adopt subtle features like increased rigidity or flexibility2. Rigidity can be 
enhanced for example, by the presence of ubiquitous pseudouridines partly by 
coordinating stabilizing water molecules3. On the other hand dihydrouridine provides 
flexibility4. Maintenance of the optimal tRNA structure however, seems to require both 
modifications, suggesting that coordination of a network of modifications is needed for 
proper stability5.
Modification of mRNA with N6-mathyladenosine (m6A), 5-methylcytidine (m5C) 
and ribose methylations have been known for decades6–8. Besides these, four additional 
base modifications have been discovered so far in mRNA: inosine (I), pseudouridine (Ψ), 
5-hydroxymethylcytidine (hm5C) and N1-methyladenosine (m1A)9. A few of these 
modifications have been well characterized, for example inosine, pseudouridine and m6A 
have been shown to influence the metabolism, function1, localization, or stability of 
transcripts to rapidly adjust the transcriptome in response to developmental and 
environmental cues10–12. Moreover m6A is found in the 5’ untranslated region and marks 
the beginning of transcripts in mRNA13. It is now clear that all these modifications in 
mRNA are not passive marks. However, research in this area is still emerging, and new 
techniques that incorporate high throughput RNA sequencing are allowing for the 
identification of hundred of additional marks in mRNA. Therefore little is known about 
their role and which are the writers (enzymes that put the marks on) and readers of these 
emerging marks. 
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1.2. RNA editing 
The term RNA editing was originally coined to describe the insertion of 4 
uridines in the coding region of the mitochondrial cytochrome oxidase subunit II gene in 
Trypanosoma brucei, which restores the frame shift encoded in the DNA14. This 
nucleotide insertion, which cannot be deduced from genomic sequence, allows for the 
formation of a functional protein, essential for generating functional mitochondrial 
proteins in trypanosomes15. The discovery of other changes in the sequence of transcripts 
led to the re-definition of RNA editing to include all type of modifications that result in 
sequence changes in the RNA from what is encoded in the genome. These modifications 
now include insertion, deletion and modification of nucleotides16.  
Modification of nucleotides is performed by the cytidine deaminase (CDA) 
superfamily of enzymes that includes both the adenosine deaminases acting on RNA 
(ADAR) and the apolipoprotein B mRNA editing catalytic polypeptide 1 (APOBEC1) 
family of proteins, as well as the adenosine deaminase acting on the tRNA (ADAT) 
family17. In higher eukaryotes, base modifications are the major type of RNA editing18. 
RNA editing is restricted to base modifications of two types: cytidines to uridines (C to 
U) and adenosines to inosines (A to I). These modifications are the result of enzymatic
deamination catalyzed by enzymes of the APOBEC1 and ADAR families, respectively 
(Figure 1.1). 
RNA editing, as well as other RNA post-transcriptional modifications like 
alternative splicing, serves to diversify the genome, expanding the limited number of 
genes given the complexity of higher organisms. Using RNA modification strategies, 
Figure 1.1 | Deamination by the ADAR and APOBEC1 families. 
Deamination of adenosine to inosine (A to I) in an RNA polynucleotide is 
catalyzed by the ADAR family of adenosine deaminases (top). APOBEC1 family 
members catalyze the deamination of cytidine to uridine (C to U; bottom). 
4
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many different gene products can be created that fill in the requirements of complex 
structural, enzymatic and regulatory functions. 
1.2.1. Adenosine deaminases 
The ADAR family of CDAs posses a conserved modular domain constitution 
consisting of a variable N-terminal domain, one to three repeats of a double stranded 
RNA-binding domain (dsRBD) and a catalytic deaminase domain in the c terminal19. The 
catalytic domain consists of amino acid residues conserved with cytidine deaminases, 
including Apobec120. Mammals have 3 ADAR proteins21, which are highly conserved in 
vertebrates. In contrast, lower metazoan organisms such as Caenorhabditis elegans22 and 
Drosophila melanogaster23 only posses one and in a few organisms, like protozoa, yeast 
and plants, ADARs are absent24. ADAR1 and ADAR2 arose early in metazoan evolution, 
proven by their presence in in sea urchin and sea anemones24. ADAR3 probably arose 
later in evolution, as a duplication of ADAR2 in vertebrates. Interestingly, ADAR was 
lost in some species such as insects and squid during subsequent evolution24.  
 ADAR1 and 2 have confirmed enzymatic ability to convert A to I in double stranded 
RNA substrates20,25–27 and are present in many cell types, with highest amounts in the 
brain28. ADAR3 is brain specific and can bind to single as well as double stranded RNA, 
but it is thought to be catalytically inactive27. The editing activity of ADARs requires 
homodimerization, being that ADAR3 can bind to ADAR 1 and 2, it is thought to act as 
an inhibitor27.  ADARs have a diverse set of substrates: ADAR 1 and 2 will edit almost 
any double stranded structure, made up of inter- or intra-molecular interactions that make 
at least 2 helical turns (~20nt)29. ADARs are also quite promiscuous, with adenosines 
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contained in long stretches of dsRNA edited ~50%. In contrast to this, short dsRNAs or 
long RNAs with imperfect mismatches (loops, bulges, etc.) are edited selectively, 
indicating that the selectivity is dictated by the secondary structure of the dsRNA30. In 
addition to the double stranded structure, selective editing requires a downstream 
complementary sequence (ECS) that is crucial for exonic editing, for example in editing 
of the Ampa receptor subunit GluR-B31.  
1.2.2. Role of ADARs in development and protein diversification 
 ADAR 1 and 2 are expressed in many tissues, whereas ADAR3 is only expressed 
in the brain20,25–27. In mouse development, ADAR 1 and 2 expressions start at around E10 
in the heart. Both ADAR1 and its regulator miR-1 are important for the embryonic heart 
development32. Models that contain deletions in ADAR genes give an insight into the 
importance of ADAR in development. ADAR1 deficient mice die quickly in utero due to 
generalized apoptosis32,33. Conditional activation studies of ADAR 1 also demonstrated 
that it is important for the maintenance of the hematopoietic stem cell33.  ADAR2 
deficient mice die soon after birth due to neurological deficiencies resulting from de-
regulated GluR34. These mice can be rescued with genomic editing of the receptor34. 
Originally, ADAR editing was thought to be restricted to ~30 transcripts, within 
coding regions. Most of these transcripts are ion channels and neurotransmitters, for 
example GluR31, the serotonin 2c-receptor G-protein subtype 5-HT2CR35 and the 
potassium channel Kv1.1A36. In these cases the recoding results in the generation of 
protein isoforms and the diversification of their functions. A mutation of a glutamine 
(CAG) to an arginine (CIG) in the GluR receptor at a site known as the Q/R site changes 
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the proteins tertiary structure such that the whole channel becomes impermeable31,37 to 
Ca2+. But the complexity does not end there. The glutamate receptor unit GluR-6 harbors 
3 exonic editing sites (known as I/V, Y/C and Q/R) that all together give rise to 8 
different sequence combinations. Because the extent of editing at each site varies 
between 10 and 80%, all possible theoretical combinations of the protein products can be 
found in the nervous system38. Just as complex is editing of five sites within 3 codons of 
the 5-HT2CR (isoleucine AUA, asparagine AAU and isoleucine AUU), which results in 
up to 6 amino acid changes and in combination, 24 receptor isoforms with variable 
potency and ligand binding35,39. Finally, 14 edited sites identified in the potassium 
channel Kv1.1 lead to many kinds of outcomes such as inhibition of tetramerization and 
changes in the rate of deactivation40. 
Editing has been implicated in certain diseases of the brain. For example, 
underediting of the Q/R site of the GluR has been observed in the death of motor neurons 
of sporadic amyotrophic lateral sclerosis (ALS) patients41. Also, the editing pattern of 5-
HT2CR mRNA is significantly altered in the prefrontal cortex of suicide victims42 .  
1.2.3. Functional roles of ADAR editing 
The protein coding ADAR-mediated modifications mentioned above are just a 
small fraction of the transcripts targeted by ADAR. Using new bioinformatic approaches, 
a wide number of sites have been discovered, mostly within inversely oriented repetitive 
elements in non-coding regions, especially within Alu regions (short interspersed 
elements that are unique to primates) and Long interspersed nuclear elements (LINE)43,44.  
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Editing of non-coding regions involves ADAR into to several processes: 
alternative splicing, nuclear retention and interaction with miRNA pathways. Alternative 
splicing can come about when ADAR targets 2 nucleotides to create a novel splice site: 
the highly conserved canonical 5’ GU (from AU) recognition sequence or the 3’ splice 
acceptor AG (form AA) site43. In the same way, it can destroy the 3’ splice site AG (from 
GG)44.  
Nuclear retention has been identified for the mouse cationic amino acid 
transporter 2 (CAT2). The mechanism is believed to involve A to I editing on SINE 
elements present within its 3’UTR, which mediate binding to the nuclear retention 
protein p54ntb. This interaction traps the RNA of CAT2 in nuclear speckles known as 
interchromatin granule clusters45. 
It has been shown that ADARS modulate different pathways of miRNA synthesis, 
leading to suppression or enhancement of miRNA processing steps. In hematopoietic 
cells for example, ADAR1 and 2 edit pri-miRNA-142, which results in degraded by the 
nuclease Tudor-SN46. Another example is the processing of pri-miRNA-151, which is 
also a substrate of both ADAR1 and 2. Editing of this pri-miRNA inhibits its cleavage by 
Dicer and its accumulation suppresses the expression of mature miRNA-15146.  
ADAR editing can also antagonize miRNA-mediated gene silencing, through 
interference with the miRNA-induced silencing complex (miRISC) assembly. One 
example where this occurs with the Epstein Barr virus encoded pri-miRNA BART6. 
Upon editing of this pri-miRNA the loading efficiency of miR-BART6 to the miRISC 
reduces, lowering the silencing of it’s target mRNA47. Additionally, mature miRNAs 
have been found to be edited and are predicted to repress a set of genes that differ from 
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those targeted by the unedited miRNAs. This is the case for miRNA-376, whose seed 
sequence is edited by ADAR2 in the +4site, essential for its binding to the 
complementary sequence in mRNA48.  
Finally, a role for miRNA regulation has been proposed for ADAR 1 and 2, 
independently from their RNA editing role. A catalytically inactive ADAR2 has been 
shown to inhibit Drosha processing of pri-miRNA-376a2 through RNA binding. 
Furthermore, there is evidence that ADAR1 can form a heterodimer complex with Dicer 
to promote cleavage of miRNAs and facilitates loading of miRNA into other silencing 
complexes49.   
1.2.4 ADARs in the innate immune response 
In its role as an adenosine deaminase, ADAR participates in the response to viral 
infection, for example in brain infections with the measles virus, samples form patient 
brains show that 2% of the nucleotides were edited, resulting in alteration of reading 
frames and fused genes50. This reaction has been characterized to involve the IFN-
inducible ADAR p150 isoform51. Another example is the hepatitis C virus (HCV) 
sensitivity to interferon-α (IFNα). Many clinical HCV infections are resistant to IFN-α 
therapy. However, subgenomic in vitro self-replicating HCV RNAs (HCV replicon) have 
a marked IFNα sensitivity52. In this case IFNα increases the expression of ADAR1 
resulting in a decrease of viral replication that leads to genomic instability. 
ADAR can also establish a proviral response, depending on the type of virus. The 
hepatitis delta virus (HDV) requires a larger version of its short DNA encoded HDV 
antigen for packaging its genome into virions. In order to do so it takes advantage of 
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ADAR1 editing to provide the change necessary for the formation of the larger HDV 
antigen by changing a UAG stop codon to a UIG tryptophan codon53. 
Another function of ADAR in the immune response is in the distinction of “self” 
dsRNA from that generated through viral infections. Viral dsRNA comes from many 
sources including dsRNA genomes, hairpin secondary structures in mRNA and 
replication of ssRNA viruses. If the dsRNA is found in the cytoplasm, it will encounter 
the retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 
(MDA5) receptors, which will induce a type I IFN response, unless dsRNA possesses 
inosine in its structure54. In this scenario, ADAR1 is a negative regulator of the type I IFN 
response by editing viral dsRNA, which is then confused as “self”, through specific 
binding to RIG-I and MDA555.  The elucidation of this process was pieced together 
though studies of ADAR deletion. First, mouse embryonic fibroblasts deficient in 
ADAR1 p150 are highly susceptible to infection and have enhanced viral induces 
cytotoxic effects51. This study implicated ADAR1 in the repression of type I IFN 
response. Also, in the search for the mechanism by which ADAR1 deletion causes 
embryonic lethality, the generation of a double mutant Adar1+/- and Mavs-/- led to the 
discovery that embryos that were homozygotes for both survived to birth54. The surviving 
embryos had a much less heightened IFN response, placing ADAR1 upstream of RIG-I 
and MDA5 in the IFN activation pathway54.  
1.2.4. Cytidine deaminases 
The AID/Apobec family of cytidine deaminases consists of several members that 
catalyze cytidine deamination in both DNA and RNA. APOBEC1 was the first member 
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of its family to be discovered and thus bears the name of its first discovered substrate 
Apolipoprotein B. Other family members include AID (Activation-induced cytidine 
deaminase), Apobec2, Apobec3 (A-H) and Apobec4. All of these share a conserved 
catalytic domain, which is zinc dependent (reviewed in Smith 2009), which has a big 
resemblance to the ancestral domain found in cytidine deaminases acting on free cytidine 
(Conticello, 2005). However, the AID/Apobec family is a later evolutionary development 
restricted to the vertebrate lineage. The first member is thought to have been AID, which 
arose concurrently with the development of adaptive immunity in vertebrates (Conticello, 
2005). 
Throughout evolution, AID/Apobec enzymes evolved rapidly, displaying the 
strongest signals of positive selection in the human genome, which is a pattern associated 
with host defense (Sawyer, 2004). For example, Apobec3, has undergone a dramatic 
expansion in primates into 8 subfamily members, in comparison to mouse, which 
possesses only one. Indeed, most family members function in immunity: AID is crucial 
for antibody diversification through somatic hypermutation and class switch 
recombination; and Apobec3’s act on both endogenous and exogenous retroviral 
genomes (reviewed in Hamilton et al., 2010). 
Until recently, the only known member of the AID/APOBEC family to act on 
RNA was Apobec1: AID is restricted to double stranded RNA, Apobec3’s to single 
stranded DNA and Apobec2 and 4 have no identified substrates. However, recent studies 
published during the course of my thesis work, have demonstrated that a member of the 
Apobec3 subfamily, Apobec3A can also edit RNA substrates56 (REF: Sharma 2015). The 
canonical role of Apobec3A is related to its DNA editing ability in the inhibition of the 
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replication of the adeno-associated virus (AAV), a small single stranded DNA 
parvovirus57. Sharma and colleagues showed that in human monocytes, Apobec3A is 
capable of editing a large number of endogenous mRNA transcripts and that editing 
increased under different physiological conditions such as hypoxia and interferon gamma 
induced inflammation56.  
1.2.5. APOBEC1 editing 
Apobec1 has a well-characterized function in the intestine, where it targets 
cytidine 6666 in the transcript of ApoB, changing a glutamine codon (CAA) to a 
termination codon (UAA)58,59 (Figure 1.2). The resulting truncated protein (ApoB48) is 
functionally different from its full-length counterpart.  This is very important for 
lipoprotein assembly and transport because ApoB is a structural protein of VLDL 
particles, whereas ApoB48 is crucial for the formation of chylomicrons. As expected, the 
loss of APOBEC1 in mice results in elevated LDL levels and cholesterol60 and is 
associated with susceptibility to atherosclerosis61.  
Editing of ApoB is regulated in a tissue specific manner through restricted 
expression of Apobec1. In adult human intestine, where Apobec1 is expressed, the 
efficiency of editing is >90%, in contrast to the liver, where ApoB remains unedited (in 
mice ApoB is highly edited in both liver and intestine). Furthermore, editing of the 
specific cytidine within the ApoB transcript seems to be exquisitely regulated and is 
correlated to Apobec1 expression levels. In order to achieve its specificity, APOBEC1 
requires the interaction with a multi-protein editing complex. The principal component of 
this complex is the RNA binding subunit Apobec-1 complementation factor (ACF), 
Figure 1.2 | APOBEC1 editing of the Apolipoprotein B transcript results in 
the creation of a smaller protein. APOBEC1 mediated deamination of cytosine 
to uridine changes a glutamate (CAA) to a stop codon (UAA), which results in 
the creation of a truncated protein, ApoB48. This is an organ-speciLic 
mechanism that allows for the creation of two different lipid particles, VLDL and 
chylomicrons, composed of ApoB100 and ApoB48 respectively. 
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which together with Apobec1 forms the minimal functional editing enzyme complex62,63. 
In contrast to Apobec158, ACF is an essential gene and mice lacking it die in the pre-
implantation stage of development64. ACF binds the transcript of ApoB through 
recognition of an 11 nucleotide mooring sequence surrounded by an AU rich 
environment. ACF has also been shown to protect the ApoB transcript with a premature 
stop codon from nonsense-mediated decay65. 
Liver –specific overexpression of Apobec1 in mice revealed Apobec1 changes its 
specificity of editing in ApoB, resulting in extensive editing at multiple cytidines 
downstream of the canonical one, a phenomenon known as hyperediting66. It is presumed 
that the reason for this loss of specificity is the altered stoichiometry of Apobec1 to ACF, 
which was confirmed with forced over expression of Apobec1 in vitro66–68. However, this 
is not the case when the ratio is altered via reduced ACF in Acf+/- mice, who exhibit 
increased hepatic editing at the ApoB canonical site but not hyperediting69. This indicates 
that there is still much to be investigated about the stoichiometry of the proteins involved 
in the regulation of the editing complex.  
1.2.6. Alternative APOBEC1 activities 
Besides its RNA editing ability, Apobec1 has been shown to have two activities 
which have been observed in vitro but that are yet to be confirmed in physiological 
conditions: modification of transcript stability and DNA editing. 
APOBEC1 has been shown to be an RNA binding protein, with specificity to AU-
rich sites, similar to the one found surrounding the ApoB mooring sequence. Specifically, 
it has been shown to bind the 3’ untranslated region (UTR) of c-myc, TNF-α and IL-2 
15	
when fused to luciferase reporters and alter their stability70. Similarly, it has been shown 
that APOBEC1 can confer stability to the cyclooxygenase-2 (COX-2) transcript, which 
contains AU-rich elements that mediate its decay, through binding of its 3’UTR, when 
cloned into a luciferase vector. Altogether, these observations suggest that Apobec1 may 
have a role in transcript stability, unrelated to its editing ability. 
When tested in a DNA mutation model, the mutation induced rifampicin-resistant 
E. coli, Apobec1 was shown to be a strong DNA mutator, displaying comparable if not 
better activity as its close relative AID71. This was also confirmed biochemically using in 
vitro deamination assays with bacteria-purified Apobec1 and DNA substrates. These 
assays revealed that Apobec1 possessed weak C to U deamination, which was restricted 
to single-stranded DNA substrates72. However, there is thus far no evidence of 
APOBEC1-induced mutations in the genome of naturally expressing Apobec1 cells. 
1.2.7 APOBEC1 in cancer 
The jury is out on whether APOBEC1 is involved in natural tumor formation. 
Evidence from over-expression models of APOBEC1 has shown that, in its role as a 
DNA editor, it is a potential oncogene. However, there is still very limited evidence that 
links APOBEC1 editing to cancer originating from patient samples. Evidence from both 
instances is presented below. 
Until recently, the only other known target of APOBEC1 editing was the 
neurofibromatosis type 1 RNA (NF1) tumor suppressor, shown to be edited in a subset of 
the patients affected with peripheral nerve sheath tumors (PNSTs)73,74. These patients 
have a particular alternatively spliced version of the Nf1 transcript, which includes exon 
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24A74. Apobec1 changes an arginine (CGA) to a translational stop codon (UGA) through 
binding to a mooring motif similar to the one in ApoB. The resulting truncated protein 
lacks the GTPase-activating protein region that is responsible for tumor suppression73. 
This finding represents the first time that Apobec1 was found to act outside of the 
intestine and opened up the possibility that Apobec1 may have alternative targets and 
therefore additional function. This shows that Apobec1 could be involved with cancer 
formation. 
A second line of evidence that APOBEC1 could be involved in cancer formation 
comes from studies in over-expression mouse models. For example, APOBEC1 caused 
hepatocellular carcinoma in mice with transgenic hepatic overexpression. Upon 
examination of edited targets, hyperediting in a novel Apobec1 target 1(Nat1) was 
identified75. Nat1 binds the initiation factor 4a (eIF4A), which inhibits both cap-
dependent and cap-independent translation. The aberrant editing alters amino acids and 
creates multiple stop codons, which in turn result in the reduction of the protein. This also 
shows an oncogenic potential for APOBEC1, however this evidence does not come from 
physiological levels of APOBEC1 expression. 
Further links of APOBEC1 with oncogenesis come from studies of testicular 
germ cell tumors (TGCTs)76 and adenocarcinoma of the small intestine in tumor-
susceptible mouse models77.  In the Apcmin/+ mouse model of small intestinal adenoma 
formation, loss of APOBEC1 reduced tumor burden, increased apoptosis and reduced 
proliferation77. However, the authors speculated that the mechanism is through the 
stabilization of transcripts such as COX-2, given that adenomas from Apcmin/+Apobec-/- 
mice had a marked reduction in Cox-2 mRNA. This could point to an editing-independent 
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oncogenic mechanism, however a genome wide search of alternative APOBEC1 targets 
was not pursued, and so the possibility remains that editing could be involved. 
However, a study that searched for aberrant APOBEC1 editing in tumor 
specimens of different types, including hepatocellular, bile duct, gastric, colorectal, 
pancreatic and breast carcinomas, failed to confirm that APOBEC1 editing is involved in 
tumor genesis of these cancers78. This is the result of either low levels of APOBEC1, such 
as in colorectal and lung carcinoma; or because whether an active version APOBEC1 or 
the required cofactors are absent from the tumor sample78.   
1.2.8. High throughput RNA seq identification of APOBEC1 editing 
After a several year hiatus, research on APOBEC1 re-emerged as new sequencing 
technologies became available and enabled the identification of new targets. In this 
section I will describe research in my laboratory that set the basis for the discovery of 
hundreds of additional sites, as well as preliminary experiments in macrophages. 
High throughput detection of RNA modifications relies on the traces that such 
modifications leave behind in cDNA, as the reverse transcriptase is confronted with non-
canonical substrates. For example, large modifications tend to lead to arrest the reverse 
transcriptase and modifications on the Watson-Crick pairing will lead to misincorporation 
of non-complementary dNTP.  The former results in shorter cDNA or abortive sequences, 
while in the latter case, the signature results in apparent mutations in the cDNA sequence. 
For example inosine, which is the result of ADAR-mediated deamination of adenosine, 
pairs with cytidine leading to the incorporation of dCTP instead of dTTP onto the cDNA. 
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These mutations can be then identified bioinformatically, through the comparison of the 
cDNA sequence to its corresponding DNA sequence. 
In order to find alternative functions for APOBEC1, we need to uncover the 
universe of sites that are edited. To do this, our laboratory developed a comparative 
approach to identify high confidence APOBEC1-mediated edited sites in a genome-wide 
manner. The method is based on the analysis of mRNA high throughput sequencing data 
taking advantage of the editing signatures in cDNA, where C to U editing causes the 
misincorporation of dATP instead of dGTP. The pipeline takes the aligned reads from the 
genome and quantifies the number of C to T mismatches in comparison to the genome. 
Then a series of filters is applied: mismatches that map to known single nucleotide 
variants are discarded. Finally, the list of the mismatches in wildtype BMDMs is 
compared to their Apobec1-/- counterparts. Bona fide editing sites are ones that occur 
only in the wildtype sample and are absent in the Apobec1-/- sample. 
This method was used to identify APOBEC1 mediated C to U editing in mouse 
intestine. As a result, 36 additional sites were identified. Interestingly, the site at the 
Apolipoprotein B transcript is the only site located at the 3'UTR; all additional sites were 
found in the 3' untranslated region of transcripts. 
1.3. Statement of purpose 
It is a very exciting time to do research in the field of epitranscriptomics given 
that, with the development of new tools, we are now able to map large numbers of 
modifications in mRNA. We know that many of them are found in tRNA and rRNA and 
are crucial for the cell.  In a similar manner, it is possible that such modifications play 
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crucial roles not only for transcript processing and fate, but also for the adaptability of 
cells to changing environments. 
One of the modifications that have been thus far overlooked is C to U editing. 
This is mainly because until recently, it was believed to be restricted to one enzyme 
(Apobec1), one substrate (ApoB) and one system (intestine). Our group uncovered a 
bigger universe of transcripts affected by Apobec1 and its physiological activity in 
immune cells. This opens up the possibility that C to U editing has a bigger role than 
previously thought. It is becoming clear that C to U editing is a widely used mechanism 
of genetic diversification that warrants further studies. 
Alternative functions of Apobec1 still remain to be established. The methods our 
group created to globally identify APOBEC1 edited sites allowed us to have a good 
catalog of APOBEC1 targets and edited sites in macrophages. In this system, ApoB is not 
expressed, which raises the possibility that Apobec1 editing has a novel role unrelated to 
lipid metabolism. I set out to provide answers, even if partial, to the following questions: 
What is the purpose of Apobec1 editing in macrophages? Does editing confer additional 
transcript regulation? Does editing regulate the activity of macrophages? 
With these questions as main motivation of my work, I focused on two main 
objectives: (1) to examine the functional consequences of editing at a molecular and cell 
level; and (2) to find out what, if any, is the role of APOBEC1 in tissues other than the 
intestine and liver.  
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CHAPTER 2. IDENTIFICATION OF HIGH CONFIDENCE EDITED SITES IN 
BONE MARROW DERIVED MACROPHAGES 
The editing detection method mentioned in section 1.2.8 (above) can be directly 
applicable to any kind of cell that expresses APOBEC1 or other editing enzymes. 
However, in an effort to improve the detection method, our group further developed a 
new method of editing identification that allowed us to confidently call low frequency 
edited sites. Our group then looked at other systems that expressed APOBEC1 in which 
it's activity could be characterized. The cell selected was bone marrow derived 
macrophages, which are cells of the immune system that express very high levels of 
APOBEC1, are readily available through differentiation of bone marrow progenitors (see 
methods) and do not express the canonical co-activator ACF nor its canonical target 
ApoB. Recently, RBM47, an RNA binding protein, was discovered to be a cofactor 
protein for Apobec1 editing of ApoB mRNA79. Rbm47 has homology with ACF and is 
able to form the core editing enzyme complex. This cofactor is expressed in BMDMs and 
is a good candidate for aiding Apobec1 editing in these cells, although this remains to be 
investigated. 
The new editing pipeline is also based on a comparative RNA-seq approach80. 
Briefly, RNA from resting wildtype and Apobec1-/- BMDMs was extracted and mRNA 
libraries were made and sequenced. Once the reads were permissively aligned to the 
reference genome, each site was scanned and mismatches to the reference genome were 
quantified. Each type of mismatch was then used to build vectors (C, T, A, G) for each 
chromosomal coordinate, with a corresponding vector for the Apobec1-/- sample. In 
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order to determine true edited sites, the angle between the two vectors is compared. A 
larger angle is a true edited coordinate (Figure 2.1). The method also incorporates filters 
for artifacts: blat filter that eliminates reads mapping to alternative genomic sites; filters 
for known variants, strand bias and variants at the end of reads, where a higher rate of 
sequencing errors reside. 
Using this method, we were able to detect 410 high-confidence C to U editing 
events in 275 transcripts. The large majority of them (97%) were contained in the 3'UTR 
of the transcripts and most of the sites were edited at low frequency 10-20% (Figure 2.2).  
We also observed that the sites could be classified into single edited and hyperedited 
(high frequency editing in one location, with additional lower frequency editing in 
alternative nearby sites, figure 2.3.B). A great number of sites were validated by Sanger 
sequencing of bacterial colonies containing fragments amplified from cDNA from 
wildtype and Apobec1-/- BMDMs (Figure 2.3). 
However, we found that the global gene expression of the genes between the two 
genotypes is highly correlated (not shown), indicating that there are no differences in 
gene expression between the two. 
Figure 2.1 | Pipeline for editing detection. (A) Depiction of vectors in a 4D 
space, built for every substitution at every base in both genotypes using data from 
the pileup. (B) Vectors for both wildtype (WT) and Apobec1-/- (KO) are 
compared and the magnitude, angle and variation between them is quantiLied. A 
high conLidence edited site possesses a large magnitude angle (left), whereas a 
low conLidence site has a low angle (right). (C) Pipeline used for bioinformatic 
detection of edited sites. 
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Figure 2.2 | Distribution of APOBEC1 editing in BMDMs. Most transcripts 
found were edited at a low rate. Transcripts with more than one edited site were 
also found.  
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Figure 2.3 | Validation of edited targets via Sanger sequencing. Examples of 
Sanger sequencing validation of bioinformatically identiLied Apobec1 C to U 
editing. (A) Comparison of a fragment of cDNA to gDNA of wildtype and 
Apobec1-/- Cd36. The edited site identiLied is highlighted in yellow (left).  
Sequences of individual colonies, aligned to the reference genome (right). Dots 
indicate matches to the reference sequence whereas mismatches are indicated 
with letters. C to T editing events are highlighted in yellow. (B) Fragment of the 
transcript App revealing sites of hyperediting. Produced by Claire Hamilton. 
24
25	
CHAPTER 3. MOLECULAR CONSEQUENCES OF APOBEC1 EDITING 
The 3’ UTR region of transcripts is a regulatory hub that controls many processes, 
such as nuclear export, stability, degradation and ribosome loading. Therefore, alterations 
in this region have the potential to result in regulation of transcript fates. This has been 
previously shown to be a possible consequence of ADAR editing81,45; therefore it is 
possible that Apobec1 editing has similar consequences.  
3.1. APOBEC1 editing in transcript fate 
Given that Apobec1 editing in BMDMs did not seem to alter gene expression 
globally, I first characterized other potential functions of 3’UTR alterations at the 
transcript level. The specificity of APOBEC1 to the 3’ untranslated region of the UTR 
suggests that editing plays a regulatory mechanism for transcripts. This has been 
previously observed for editing enzymes of the ADAR family. ADAR editing has been 
shown to have the potential to alter transcript stability81 and localization45, causing 
nuclear retention of the edited transcript. To test whether APOBEC1 editing resulted in 
altered localization of transcripts, I designed a cell fractionation experiment to compare 
the levels of editing between the cytoplasmic and nuclear fractions. I selected various 
transcripts that had different levels of editing at a single site, as well as hyperediting. 
After cell fractionation using cell lysis buffers with different composition of surfactants, I 
was able to isolate cytoplasm, nucleus and chromatin. Then, I extracted RNA form each 
fraction, made cDNA and tested for abundance of each transcript using qPCR. 
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In order to compare the frequency of editing at each site in the cytoplasm and 
nucleus, I amplified a region surrounding the edited site and submitted individual 
bacterial clones for Sanger sequencing. Western blot analysis of the different fractions 
using the antibodies for the histone H3 and tubulin confirmed the purity of the nuclear 
and cytoplasmic fractions respectively (not shown). 
As expected, I found that all edited transcripts in the wildtype sample were edited 
in the nucleus. This is consistent with the previously reported mode of action of 
APOBEC110. Figure 3.1.1 shows two examples of editing in the different fractions of 
wildtype samples.  Individual sequences derived from the colony sequencing, amplified 
from each of the fraction’s cDNA, were aligned to the reference genome.  Using this 
data, I quantified the fraction of edited transcripts, counting as edited any transcript with 
at least one C-T change in the whole length of the amplified fragment, even if the 
previously predicted site did not show editing. As can be seen in Figure 3.1.2.A, the 
fraction of edited transcripts in the nucleus is very similar to the cytoplasm, which 
indicates that editing does not cause selective retention of edited transcripts in the 
nucleus. This is confirmed by the qPCR data in Figure 3.1.2.B, which shows that, even 
though the amount of transcripts within the nucleus is higher than in the cytoplasm, there 
is no difference between the transcripts of wildtype and Apobec1-/- BMDMs. 
An alternative mechanism of transcript regulation that could be affected by 
editing is the stability of transcripts. To test whether editing would increase or decrease 
transcript stability, I quantified several edited transcripts at different time points upon 
addition of actinomycin D to the cell culture, which inhibits transcription.  This allows 
for evaluation of the decay of transcripts, because no new ones are added to the pool. In 
Figure 3.1.1 | Effect of editing in transcript localization. Aligned sequences of 
the PCR fragments amplified around the edited sites of the Lamp1 and B2m 
3’UTRs. The C to T changes, with respect to the genomic sequence, are 
highlighted in yellow.  
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Figure 3.1.2 | Effect of editing in transcript localization. (A) Quantification of 
the fraction of edited transcripts in the nuclear and cytoplasmic cell  fractions 
(n=3). (B) Relative levels of transcripts in the nuclear and cytoplasmic fractions 
of wildtype and Apobec1-/- BMDMs. Transcript levels were normalized to Gapdh. 
All error bars represent the standard error of the mean.
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addition to the edited transcripts, I also quantified known stable and unstable transcripts 
for comparison. The decay of edited transcripts in both wildtype and Apobec1-/- BMDMs 
was quantified via qPCR and plotted. Figure 3.1.3 shows that, as expected, there remains 
above 50% of the known stable transcript Atp5a1 after 4 hours after Actinomycin D 
addition, whereas there is almost no trace of the unstable transcript Jun at the same time. 
When the edited transcripts were examined, I observed that they are stable, such that 
there is at least 50% transcript left after 4 hours. 
This is interesting, given that it has been demonstrated that Apobec1 directly 
binds transcripts with fast turnover, increasing their stability, but in this case, edited 
transcripts are long-lived. Perhaps this dynamic is dependent on co-factor utilization. 
Interestingly, the stability of Apobec1-/- transcripts is very similar to their wildtype 
counterparts, indicating that editing does not modify transcript stability.  
3.2. miRNA regulation through editing 
APOBEC1-dependent 3′UTR edits were previously described to be preferentially
located in regions of substantial phylogenetic conservation82. Conserved untranslated 
regions are also regions of abundant Argonaute (Ago) occupancy and resultant miRNA 
targeting83, raising the possibility that APOBEC1 editing might influence transcript 
regulation by miRNAs. Our group previously investigated whether the alteration of 
3’UTRs leads to the change of microRNA binding sites using the CLIP-seq84 technique. 
This consists on immunoprecipitation of the RNA binding protein Argonaute, followed 
by protein digestion and library preparation of the resulting fragments. The two types of 
RNA obtained after this procedure are miRNAs and mRNAs that are interacting with 
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Argonaute at the moment of cell lysis. The mRNA fragment represents only the fraction 
protected by Argonaute, therefore it is possible to bioinformatically identify the possible 
miRNA target sites within this footprint and predict which miRNAs are active. 
Indeed, high-throughput sequencing of the mRNA and miRNA fragments 
revealed that Argonaute significantly bound the subset of transcripts edited by 
APOBEC1, even though the comparison of wildtype and Apobec1-/- revealed there was 
no differential binding of Argonaute. Therefore, we focused on the subset of 3'UTRs 
where Ago occupancy overlapped with edited sites and assigned to these a set of likely 
miRNA targets, selected based on miRNA abundance and recently defined rules for 
canonical as well as non-canonical binding85. Upon examination of the mRNA from the 
footprint, we bioinformatically identified several miRNA binding sites that were 
potentially created or destroyed by C to U editing, which are candidates for miRNA 
regulation through APOBEC1 editing (Figure 3.2.1). 
In order to determine whether a single nucleotide change is sufficient for the 
disruption of a miRNA binding site, we performed luciferase assays using a fusion of the 
luciferase reporter to the edited version of several 3’UTRs. We cloned edited and 
unedited 3′UTRs into dual-luciferase expression vectors and co-transfected them with
their putative miRNA in HEK-293T cells (or an irrelevant control miRNA) in the 
absence of APOBEC1. We identified 3′UTRs (e.g. Sptssa and Rac1) where editing
disrupts predicted miRNA-UTR interactions, resulting in de-repression of luciferase 
levels in the edited construct, as compared with the unedited construct (Figure 3.2.2). 
Two of the four miRNA tested were indeed disrupted by editing. This demonstrated that 
for some miRNAs, a C-T change in the binding sequence is sufficient to eliminate the 
Figure  3.2.1  |  Putative  miRNA targets  in  APOBEC1-edited  regions  that 
overlap  with  Ago  footprints.  “Edited”  (with  C-to-T  mutations  reflecting 
APOBEC1-dependent  changes)  and  “Unedited”  (reflecting  the  genomic 
reference) footprint sequences were scanned for miRNA targets regions (match to 
position 2-7, 1-6 or 3-8 of mature miRNA sequence). miRNA targets that would 
be created (green) or disrupted (red) by an APOBEC1 editing event are depicted. 
Figure produced by Dewi Harjanto.  
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Figure  3.2.2  |  APOBEC1  editing  disruption  of  putative  miRNA  target 
regions  in  the  Sptssa  and  Rac1  3UTRs.  UN-  refers  to  the  “unedited” 
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interaction between miRNA and mRNA. This serves as proof of concept that 
demonstrates that under some circumstances, C to U editing has the ability to disrupt 
repression through miRNA binding. However, further research is required to figure out 
the rules that govern transcript de-repression and the extent to which edited transcripts 
are targets of miRNA binding. 
3.3. Editing alters protein production though miRNA independent mechanisms 
The overlap between edited sites and Argonaute binding is, however, not 
complete. The vast majority of edited transcripts have no predicted Argonaute binding. 
Therefore I tested whether editing events that did not alter a putative miRNA binding 
sites could also lead to modulation of protein expression. In order to test this, I created 
luciferase constructs that contain either the unedited or edited version of several 3’UTRs 
fused to the renilla luciferase gene. Additionally, these constructs contain the firefly 
luciferase gene, which is co-expressed and used as a transfection control. Each construct 
was then introduced into Apobec1-/- BMDMs (which contain the physiologically 
relevant milieu of RNA binding factors), to avoid further editing, and luciferase levels 
were quantified 24h later. Figure 3.3.1.A shows that from the singly edited constructs, 
only the edited 3’ UTR of Cd36 showed a decrease in protein product. On the other hand, 
all hyperedited transcripts showed different levels of regulation (Figure 3.3.2A), albeit 
small. This experiment also allows us to determine the effect of editing separate from any 
alternative activity of APOBEC1, and confirms that the effect in protein modulation is 
the direct result of C to U modifications.  
Figure  3.3.1  |  Editing  can  modulate  protein  expression.  (A)  Luciferase 
experiments of single-edited constructs. (B) Expression of CD36 in the surface of 
BMDMs (FACS).
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Figure  3.3.2  |  Editing  can  modulate  protein  expression.  (A)  Luciferase 
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25% most highly expressed genes. 
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We then tested whether we could observe differences in the endogenous protein 
levels of some of the transcripts tested via luciferase assays. We compared the levels of 
LAMP1,  B2M and CD36 in wildtype and Apobec1-/- BMDMs, via flow cytometry. We 
only observed differences in total and cell surface levels of CD36 (Figure 3.3.1.B), which 
is consistent with the luciferase experiments. This particular transcript has the special 
characteristic that it is both highly edited (80% frequency of editing) and robustly 
translated. We therefore speculate that in order to see differences in the expression of 
protein products of editing trascripts in the cell, a transcript would need to be both highly 
translated and highly edited, as is the case of CD36.   
In order to test globally whether edited transcripts result in differences of protein 
production, we considered two methods, SILAC and Ribo-seq. SILAC is a method that 
uses mass spectrometry to determine the differences between two cell populations, one of 
which is labeled with non-radioactive isotopic labeling86. However, the sensitivity of 
detection is only very good for highly expressed proteins, and thus cannot access the 
entire proteome. Many of the APOBEC1 modified transcripts are not highly expressed, 
which is an obstacle for using SILAC. 
Ribo-seq is a technique that surveys transcriptome-wide ribosome binding. It uses 
high throughput RNA sequencing after polyribosome pool down to determine the ratio 
between expressed total RNA and the RNA being translated. This measure has been 
shown to be a much better estimation of protein abundance than total RNA87. Riboseq has 
the advantge over SILAC of being able to detect small changes and access lowly 
expressed transcripts. Given that editing does not happen at an efficiency of 100%, we 
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expect that the differences we may find when comparing wildtype vs. Apobec1-/- 
ribosome binding are small. 
We therefore performed Ribo-seq using wildtype and Apobec1-/- BMDMs. First, 
cell lysate was split in two samples. The first one was treated with nuclease to degrade 
RNA unprotected by ribosomes. Then the polyribosomes were selected through column 
separation and the protected RNA was extracted for ribosomal RNA depletion, reverse 
transcription and library preparation. The second sample was used for total RNA 
extraction, followed by ribosomal depletion and library preparation. Both samples were 
then sequenced using a lane in the Illumina nextseq and reads were aligned to the 
genome. Ribosomal quantification and gene expression were calculated using DEseq. 
Translational efficiency was calculated using the coefficient of RPF / mRNA87, and this 
was used to asses differential loading between wildtype and Apobec1-/- samples. We 
found that the ribo-seq libraries had a lot of variability between samples and were very 
prone to batch effects, therefore we decided to analyze the top 25% most expressed 
genes. These included the majority of edited transcripts. Figure 3.3.2.B shows there are 
no differences in ribosomal binding between wildtype and Apobec1-/- except for 
Apobec1; and confirms there are no transcriptional differences between the two 
genotypes either. 
The lack of translational differences observed in the Ribosome capture assay 
indicates that the effect of editing in protein expression is either very minimal, or that at 
the level of population, the changes in individual cells with higher degree of editing get 
lost in the mix. In the next chapter, the possiblility that cells are heterogeneous in terms 
of editing is addressed. On the other hand, an analysis of either protein abundance or 
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ribosome binding at the single cell level are experiments which require technology not 
available at the moment, so differences at this level will remain to be tested. 
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Chapter 4. APOBEC1 editing contributes to cell heterogeneity 
APOBEC1 targets 68 different transcripts in resting BMDMs, mostly through 
single site editing. These transcripts are targeted with varying frequencies (from ~10%, 
our arbitrary lower threshold, to close to 100%). Given that APOBEC1 editing has a 
moderate effect on protein levels, we were curious as to whether the varying editing 
efficiencies of transcripts at the population level were the result of uniform editing in all 
cells, or of high levels of editing in a subset of cells (both possibilities would generate 
similar population-wide RNA-seq profiles; Figure 4.1.A). This has been a long-standing 
question in the editing field because most of known editing occurs at low frequency for 
both ADAR and APOBEC1 editing, rising questions about the biological significance of 
editing in aggregate. To explain this phenomenon, two hypotheses have been created. 
The first one, proposed by Gommans and Maas, states that such low frequency editing 
events may be a way of creating “noise” that perhaps may fulfill a biological function as 
an alternative mechanism to genomic-level mutations for probing potentially 
advantageous adaptations. Therefore, in their theory, editing at the population level is an 
accurate representation of editing in individual cells88. An alternative hypothesis, 
presented by Pullirsch and Jantsch, is that RNA editing can diversify cell populations by 
actually occurring at a very high frequency in specific subsets of cells89. To distinguish 
between them, we used single-cell RNA-Seq to profile editing in individual resting 
BMDMs and compared these to a bulk population sample. 
Figure 4.1 | Single cell sequencing. (A) Example plot showing high correlation 
between gene expressions of single wildtype  vs. Apobec1-/-  BMDM cells. (B) 
Comparison of the gene expression of the ensemble of all sequenced single cells 
vs. the bulk population. 
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4.1. Single cell sequencing 
To determine whether there is heterogeneity in terms of editing within the 
macrophage population, we performed single-cell high throughput sequencing, using the 
C1 system from Fluidigm. Wildtype and Apobec1-/- BMDMs were sorted into C1 chips 
where cells were lysed and the RNA was reverse transcribed. Next, single cell libraries 
were made using the Illumina Nextera system and sequenced in a lane of an Illumina 
Hiseq. 
Gene expression of single wildtype cells was compared to their Apobec1-/- 
counterparts. As observed when comparing bulk populations, there is also a high 
correlation between the two phenotypes (all possible combinations were analyzed; Figure 
4.1.B shows an example of one such pair). 
The comparison of the gene expression levels of bulk RNA-Seq (of a population 
of BMDMs) and the ensemble of all single cell replicates showed a tight correlation 
(r>0.99; Figure 4.1.C), indicating that the gene expression signature obtained from the 
single cells is a good representation of the bulk population. This also shows an apparent 
lack of heterogeneity at the transcript expression level in un-stimulated single cells. This 
has precedent in bone marrow-derived DCs, where resting cells start off as 
transcriptionally homogeneous, with variation at the level of expression introduced 
shortly after stimulation90.  
Furthermore, highly expressed transcripts, such as B2m showed little variability in 
expression levels in single cell libraries. However, that is not the case for most edited 
transcripts (Figure 4.2.1, left); the mid and lowest expressed transcripts showed the most 
variability between cells, which is consistent with previous reports91.   
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Figure  4.2.1  |  Editing  distribution  in  single  BMDMs.  Coverage  (left)  and 
editing rates (right) for high confidence C-to-U edited sites in the 24 single-cell 
and  bulk  macrophage  RNA-seq  data  sets.  Bottom:  expression  levels  of 
APOBEC1 in transcript per million. Sites are sorted in order of descending bulk 
editing rate. Produced by Dewi Harjanto.
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4.2. Analysis of the variability of editing rates per site across single cells 
Single cell sequencing has been shown to have several characteristics. Due to the 
small amount of starting material and the efficiency of reverse transcription, it is not 
possible to access the entire transcriptome, which results in an underrepresentation of 
lowly expressed transcripts. Also, the reverse transcription is primed with polyA oligos, 
therefore the reads are enriched at the 3’ end of transcripts. These characteristics are not 
problematic when these reads are used for gene expression analysis92. However, editing 
detection requires sites to be well covered and reads to be properly mapped. The low 
capture efficiency in single cell sequencing, estimated at around 20%93, is the major 
obstacle for using editing detection algorithms, especially for lowly edited or expressed 
transcripts. 
Due to these sampling issues, if a site is not edited, there could be two 
possibilities: that the site is genuinely not edited in the cell’s transcriptome; or that the 
edited transcripts were present but were not captured during library preparation and 
sequencing. When examining editing at the high confidence sites identified from the bulk 
RNA-seq, across the single cells, we observed that, editing is present in at least one of the 
cells (402 of the 410 sites were covered in at least one cell and 22 of those sites was 
edited in at least one cell; Figure 4.2.1, left). However, editing levels did not necessarily 
correlate with APOBEC1 levels (Figure 4.2.1, right-bottom). Within these sites, we can 
also observe a wide range of editing rates. For example, the site in the Cybb transcript 
(indicated in Figure 4.2.1, right), which is covered uniformly in all cells, is edited in 
61.5% of the reads in cell 6 while it isn’t edited at all in 11 other cells (compared to just 
23% in the bulk experiment). 
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Whereas it would seem from looking at Figure 4.2.1 that there is indeed 
heterogeneity in terms of editing among the single cells, the stochasticity inherent in the 
single cell RNA-seq method has to be accounted for. To ascertain variability within the 
APOBEC1-mediated editing rates from single cells, in comparison to the bulk editing 
rates recovered form populations of cells, a more sophisticated statistical method had to 
be developed. In order to do this, we collaborated with a group of statisticians at the 
University of Warwick∗ to model the level of variability of editing rates per site across 
single cells and in bulk samples. They created a hierarchical Bayesian method80 to model 
the behavior of variable and homogeneous cells, and determined the profiles that each 
scenario would result in (Figure 4.2.2). Essentially, a population with high variability 
would have a high variability in the posterior distribution and a wide range of p values 
(Figure 4.2.2, top), whereas a homogeneous population would have a low posterior 
variance and narrow p values (Figure 4.2.2, bottom). When comparing these to the 
experimental data, they determined that there is a wide range of variability: they could 
find instances of transcripts edited with low, mid and high variance across cells (Figure 
4.2.3. A, B and C, respectively).   
4.3. Experimental validation of editing heterogeneity 
To validate the predictions made by the model, we designed an RT-PCR 
amplification method to specifically look at different regions of transcripts that are 
editable. In order to carefully do molecular quantification of the edited transcripts, I 
designed gene specific RT-primers with a 6 nucleotide barcode, which are sufficient to 
∗ Theodore Papamarkou, Chris J. Oates & Anastasia Papavasiliou; Department of Statistics, University of 
Warwick, UK. 
Figure 4.2.2 | Effect of changing the levels of variance on model. Histograms 
of variance of editing rates (left),  editing rates (middle) for two artificial data 
sets, one with high editing rate variance (top); and the other with low editing rate 
variance (bottom). Produced by Dewi Harjanto.
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Figure  4.2.3  |  Application  of  the  Bayesian  model  to  macrophages. 
Simulations  ran  on  24  single-cell  data  for  B2m,  Anxa5  and  Cybb.  Left: 
histograms of variance of editing rates, across all 24 cells; right: histograms of 
editing rates, denoting the distributions of editing rates for each cell (each cell is 
labeled with a different color). Produced by Dewi Harjanto.
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capture 4096 unique transcripts, a more than adequate amount to characterize the 
diversity within a single cell93. The fragments were then cloned into bacteria and 
sequenced using Sanger sequencing. Using the barcodes, I could discriminate fragments 
that are the result of PCR duplication and remove them from the analysis. This allowed 
us to examine the different sites with substantial depth, which is the main limitation of 
the high-throughput approach. Figure 4.3.1 shows the location of the edited sites in 
several single cells. The edited transcripts are labeled in red. The results from this 
experiment align well with the model predictions. In the case of Cybb, for which the 
posterior distribution in the model suggests high variability, we observed that there exist 
cells that have very high levels of editing (Figure 4.3.1.C, cells #1, 2 and 6) along with 
ones very low levels (Figure 4.3.1.C, cells #4, 5 and 7). Similarly, in the case of B2m and 
Anxa5, for which the model predicted lower variability, we can see that cells are roughly 
uniformly edited (Figure 4.3.1.A and B). 
When we examined the whole of the amplified region (300nt fragments; Figure 
4.3.2), we were able to identify editing that occurred at different sites from the 
bioinformatically determined ones. In the case of Anxa5, we observed that there is 
substantial editing in these alternative sites, which was not apparent from the bulk 
sequencing. This is perhaps because of the stringent filters in the bioinformatics 
algorithms used to identify editing. Transcripts where editing exists in an alternative site 
are also labeled in red on Figure 4.3.2. 
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Figure 4.3.1 | Validation of model predictions using targeted amplification of 
editable sites from single cells.  Sequence alignments from targeted RT–PCR 
amplification and Sanger sequencing of bacterial colonies for B2m, Anxa5 and 
Cybb transcripts from gDNA and cDNA from a bulk sample and cDNA of single 
cells.  Alignments  are  colour-coded  to  indicate  whether  the  sequence  aligned 
contained (red) or lacked (grey) editing in the length of the amplicon.  
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Figure 4.3.2 | Editing at sites alternative to the bioinformatically identified 
site. The alignment of a single cell is shown for B2m, Anxa5 and Cybb. The site 
shown in figure # is shown in grey. Alternative C to T changes are shown as T’s 
within the alignments.
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CHAPTER 5. FUNCTIONAL CONSEQUENCES OF APOBEC1 EDITING IN 
MONOCYTES 
At a molecular level, editing is involved in the modulation of protein expression, 
either through the modification of miRNA binding or through alternative mechanisms. 
This is significant because even though editing occurs in low frequency at the population 
level, there is substantial variability between cells, raising the possibility that subsets of 
the population have specific characteristics. This variability between cells is reminiscent 
of the variability that has been described for monocyte populations and their plasticity, 
which allows them to respond to fluctuating environmental cues94,95. This is crucial to the 
maintanance of homeostasis as monocytes perform many crucial roles for the organism 
such as removal of debris and the production of tissue maintanance factors. 
However, they also have the ability to react towards foreign antigens and help 
orchestrate an inflammatory response. Finally, in order to protect the body from 
exaggerated inflammatory responses, they are also invoved in the repression of the 
response and tissue repair.  It has been long though that these responses are performed by 
subsets of macrophages that have one of two phenotypes, M1 (inflammatory or 
classically activated macrophages) or M2 (homeostatic or alternatively activated 
macrophages). However, it is becoming clear that there is more of a spectrum rather than 
a binary classification for monocytes and that these cells are very plastic, being ablet to 
change from one phenotype to another. We therefore evaluated whether the lack of 
editing had consequences in the activity of macrophages. 
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Previous investigations of the functional consequences of RNA editing have 
focused on instances where transcripts are edited with very high frequency and with clear 
biological implications (e.g. APOBEC1 editing of Apolipoprotein B96,97). However, the 
collective functional consequence of targeting a large number of transcripts has never 
been examined. In order to find relevant processes that could be modulated by editing, I 
looked for pathway enrichment of edited transcripts using the online database DAVID 
(Broad Institute). Because this database is a repository of all genes regardless of origin, it 
identifies non macophage-specific pathways, although many of the pathways identified 
are pertinent to immune cells. APOBEC1 edited transcripts in BMDMs encode proteins 
important for lysosome maturation (e.g. Lamp1, Lamp2, Atp6ap1) and phagocytosis, as 
well as proteins important for migration (e.g. Rac1, Kras, Pak2, Brb2; Table 5.1). Given 
that editing can affect protein abundance, we asked whether small alterations in the levels 
of such proteins could collectively alter cell physiology. Therefore, we assessed the 
relative performance of wildtype and Apobec1-/- BMDMs in both phagocytosis and 
migration. 
5.1. Editing deficient BMDMs display altered migration and phagocytic capacities 
One of the early consequences of chemokine signaling in BMDMs is directed cell 
migration. In order to test whether migration is altered in editing-deficient BMDMs, we 
designed a migration test where BMDMs are placed in the upper chamber of a two 
chamber culture dish. We determined from the RNA-seq data that the highest expressed 
chemokine receptor in BMDMs is CXCR4, whose preferential ligand is CXCL12 (also 
known as stromal-derived-factor-1). Expression of CXCR4 was confirmed via flow 
Term	 PValue	 Genes	 FoldEnrichment	 FDR
Lysosome	 3.0E-04	 CTSL,	LAMP2,	SLC17A5,	AP1S2,	IDS,GNPTAB,	TPP1,	ATP6AP1,	ASAH1,	CTSF	 4.5	 0.338	
B	cell	receptor	
signaling	pathway	 6.0E-04	 NRAS,	KRAS,	GRB2,	RAC1,	PPP3CB,PPP3R1,	PPP3CA,	NFATC3	 5.4	 0.681	
VEGF	signaling	
pathway	 2.5E-03	 NRAS,	KRAS,	RAC1,	PPP3CB,	PPP3R1,PPP3CA,	NFATC3	 5.0	 2.849	
T	cell	receptor	
signaling	pathway	 5.6E-03	 NRAS,	KRAS,	PAK2,	GRB2,	PPP3CB,PPP3R1,	PPP3CA,	NFATC3	 3.7	 6.248	
Natural	killer	cell	
mediated	cytotoxicity	 6.7E-03	 NRAS,	KRAS,	GRB2,	RAC1,	PPP3CB,PPP3R1,	PPP3CA,	NFATC3	 3.5	 7.438	
Sphingolipid	
metabolism	 6.9E-03	 SGPL1,	SPTLC1,	SGPP1,	ASAH1,	DEGS1	 6.4	 7.670	
MAPK	signaling	
pathway	 2.2E-02	 NRAS,	KRAS,	PAK2,	GRB2,	RAC1,	TGFBR2,	PPP3CB,	PPP3R1,	PPP3CA,	PRKACB,	GADD45A	 2.2	 22.920	
Chemokine	signaling	
pathway	 4.8E-02	 NRAS,	KRAS,	GRB2,	GNG10,	PREX1,	RAC1,PRKACB,	CCL5	 2.4	 43.365	
N-Glycan	biosynthesis	 5.1E-02	 STT3B,	MAN2A1,	MGAT2,	FUT8	 4.7	 45.240	
PPAR	signaling	
pathway	 5.6E-02	 LPL,	CD36,	GYK,	ACSL4,	CPT1A	 3.4	 48.305	
Apoptosis	 7.4E-02	 CASP6,	PPP3CB,	PPP3R1,	PPP3CA,	PRKACB	 3.1	 58.746	
Cell	cycle	 8.5E-02	 E2F4,	HDAC2,	RAD21,	RBL2,	MCM4,GADD45A	 2.5	 63.660	
Table  5.1  |  Pathway  enrichment  analysis  using  the  subset  of  edited 
transcripts.  Sites  found  in  BMDM  were  fed  to  the  pathway  identification 
website DAVID from the Broad Institute. Significant pathways related to immune 
cell activity are presented. 
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cytometry in both wildtype and Apobec1-/- BMDMs, which didn not display differences 
in cell surface expression of the receptor. Therefore we chose to teste migration towards 
this chemokine. Briefly, different concentrations of the chemokine CXCL12 were placed 
in the lower chambers of a two chamber culture dish and the BMDMs were placed in the 
top chambers. Media without serum was used as a control for basal migration and the 
amount of migrated cells was determined 4h later using a fluorescent dye that binds to 
DNA. The median fluorescence intensity is directly correlated to the amount of DNA in 
each well, which is a good reflection of the number of migrated cells. Migration is 
reported as the chemokine index, which is a relative measurement that is calculated 
normalizing to the basal migration. As shown in Figure 5.1.A, APOBEC1-deficient 
macrophages have a very reduced migration capability. We speculate that because there 
are no differences in CXCR4 receptor expression, the altered migration phenotype of 
Apobec1-/- BMDMs is the result of differences in downstream signalling molecules (e.g. 
Ras) or cytoskeleton remodelation (e.g. Rac), both of which are good  starting points for 
future studies. 
To test phagocytosis, we added pHrodo-labeled S. aureus particles at two 
different multiplicities of infection (MOI) to BMDMs cultures. These particles are 
colorless until they reach the acidic environment of the lysosome, where they fluoresce. 
Phagocytosis can thus be directly quantified by flow cytometry 20 min later. 
Surprisingly, Apobec1-/- BMDMs showed an increased amount of particle uptake, 
compared to wildtype counterparts (Figure 5.1.B), therefore, lack of editing leads to 
increased phagocytosis. It has been shown before that an over-abundance of LAMP1 and 
of other proteins involved in phagosome maturation leads to an increase in phagosome 
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Figure  5.1  |  APOBEC1  is  required  for  the  proper  phagocytosis  and 
migration  in  vitro.  (A)  Quantification  of  migration  towards  CXCL12  (also 
known as SDF-1). Error bars represent the standard error of the mean, statistical 
analysis  was  performed  using  the  multiple  measured  one-way  analysis  of 
variance, followed by a t test with Bonferroni’s correction; n=3; *p< 0.05, **p< 
0.01, ***p< 0.0001). (B) Phagocytosis of S. aureus pHrodo particles (aggregate 
of  n=5).  Error  bars  represent  the  standard  error  of  the  mean;  statistical 
significance was obtained using a t-test. MOI stands for multiplicity of infection. 
(A) was done in collaboration with Yamina Berchiche.
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maturation98. We speculate that this may be one of the reasons why Apobec1-/- cells (or a 
subset of them) that potentially have increased levels of Lamp1, have an increased 
capacity to uptake the beads. 
Interestingly, Apobec1-/- BMDMs are poor at an essential activity of 
macrophages but not at an equally fundamental one, specially because the two activities, 
even though independent from each other, are very related (e.g. cells need to migrate to 
sites of infection in order to ingest bacterial invaders). We can speculate that this could be 
the result of the variability of editing between the cells and how this affects specific 
pathways in different cell subsets. However, this remains to be tested. 
5.2. Editing is necessary for proper monocyte differentiation 
The differences in macrophage activity observed in vitro suggest that Apobec1-/- 
mice ought to have alterations in monocyte activity. In order to find clues for Apobec1-
mediated regulation in the physiology if mice, I performed a phenotypic characterization 
analysis of Apobec1-/- mice, that included a complete blood count, blood chemistry and 
organ dissection and staining∗ (results not shown).  I also characterized the different
immune populations in bone marrow, blood, and spleen via flow cytometry (not shown). 
With all of this information, I concluded that, besides the already published increase in 
the low density lipoprotein fraction and a reduction in high density lipoprotein cholesterol 
resulting from impaired ApoB editing60,99, there are no additional physiological 
differences in the Apobec1-/- mice when compared to their wildtype counterparts. 
∗ This work was done by the Laboratory of Comparative Pathology at Memorial Sloan-Kettering Cancer 
Center 
57	
However, any differences in monocytes in vivo could be obscured as a result of 
compensation mechanisms. In order to study monocytes in vivo and have a direct 
comparison of wildtype and Apobec1-/- monocytes, which have been differentiated in the 
same milieu, we turned to a competitive reconstitution experiment. This experiment 
allows us to look at monocytes developing before compensations mechanisms can kick in 
and also has the advantage that reconstituting wildtype mice allows for proper 
APOBEC1-editing in intestine and liver. This allows us to isolate cell-autonomous, 
APOBEC1-dependent effects on the monocyte lineage in the absence of other known 
APOBEC1 related phenotypes (e.g. intestinal editing of Apolipoprotein B). 
The competitive reconstitution experiment consists of placing Apobec1-/- 
monocytes along with their wildtype counterparts in a wildtype environment in vivo, thus 
having a direct comparison of their activity when challenged. One of the ways in which 
we can obtain both populations within wildtype mice is through the creation of chimeras. 
This can be achieved through bone marrow reconstitution of irradiated mice with bone 
marrow progenitor cells. After these chimeric mice establish the monocyte populations, 
we can challenge them and test macrophage differential activity. 
Specifically, I injected equal numbers of bone marrow progenitors from wildtype 
(CD45.1) and Apobec1-/- (CD45.2) bone marrow into lethally irradiated syngeneic hosts 
and tested for reconstitution of monocytic populations in spleen via flow cytometry 
(Figure 5.2.1). The reconstitution of monocytes is one of the earliest events after bone 
marrow transplantation; we observed monocyte populations in spleen as early as 3 weeks 
(Figure 5.2.2.A). However, other cells, such as B and T cells have much longer 
reconstitution times. 
Figure 5.2.1 | Analysis of spleen chimeras. Splenocytes were stained with 
a cocktail of antibodies and analyzed via flow cytometry. The gating used 
to separate the populations are indicated.
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Figure 5.2.2 | APOBEC1 deficient mice have altered monocyte populations. 
(A) Analysis of spleen in radiation chimeras reconstituted with an equal number 
of wildtype and Apobec1-/- lineage-negative bone marrow progenitors (n=6). (B) 
APOBEC1  expression  in  sorted  monocyte  progenitors,  relative  to  Gapdh 
expression. MDP: monocyte dendritic cell progenitor; cMOP: common monocyte 
progenitor.  (E)  Analysis  of  bone  marrow monocyte  progenitor  populations  in 
radiation  chimeras  reconstituted  with  an  equal  numbers  of  wildtype  and 
Apobec1-/- progenitor cells, 6 weeks after transplant (n=6). 
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Surprisingly, when we compared the ability of each progenitor to reconstitute 
monocyte populations in spleen, we found that, even though the progenitors were mixed 
in a 1:1 ratio, the Apobec1-/- progenitors outcompeted their wildtype counterparts and 
gave rise to significantly increased numbers of M1-like (Ly6C+) monocytes in the spleen 
at 6 weeks, a trend that initiated at 3 weeks (Figure 4.2.2.A). Meanwhile, the frequency 
of the other major type of monocyte, M2-like (Ly6C-), was not altered (Figure 5.2.2.A). 
In a separate experiment, we also irradiated Apobec1-/- and Apobec1+/- mice and 
reconstituted them with a 1:1 mix of progenitors. Under these conditions, the Apobec1-/- 
progenitors also generated increased monocytic populations in spleen (not shown). This 
demonstrates there are no significant numbers of radiation-resistant cells at 3 weeks post-
transplant, which could bias the results of the reconstitution. Also, this indicates that the 
effect is cell intrinsic. 
To test whether the increase in Ly6C+ monocytes is due to an increase in their 
proliferative capacity, I tested for expression of Ki-67, a nuclear marker specifically 
found in proliferating cell100, via flow cytometry. I did not observe Ki-67 expression in 
Ly6C+ monocytes (not shown), which suggests these cells are not proliferating. 
Alternatively, the increased number of Apobec1-/- Ly6c+ cells in spleen could be the 
result of increased output from the progenitor cells, increased cell division of mature 
monocytes or increased migration of monocytes into the spleen. We had previously 
observed that BMDMs have decreased migratory ability towards CCL12; however, this 
seems not to be the case in vivo. This could be the result of differences between 
monocytes and BMDMs, which are an artificially derived mature form of macrophages, 
as compared to monocytes, which are a more immature subset. However, it could also be 
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that the migration phenotype is restricted to signaling through CXCR4, which has been 
shown to mediate retention of monocytes in the bone marrow101. If this mechanism of 
retention is indeed impaired in Apobec1-/- monocytes, it is possible they would exhibit 
increased exit from the bone marrow. 
Alternatively, APOBEC1 could be regulating the developmental progression of 
specific subsets of cells in the bone marrow. In order to test this I quantified the 
expression of APOBEC1 in monocyte subsets and bone marrow monocyte progenitors 
via qPCR, in sorted populations. APOBEC1 is expressed early in monocyte 
differentiation, and its transcript levels are highest in the common monocyte progenitor 
(cMOP) cells (Figure 5.2.2.B). This could mean that in vivo, APOBEC1’s function is 
involved in monocyte differentiation. To test whether the increase of Ly6C+ monocytes 
is the result of increased progenitor cells, I quantified the number of these progenitors in 
bone marrow after reconstitution. Apobec1-/- cMOP cells outcompeted their wildtype 
counterparts at 6 weeks after transplant (Figure 5.2.2.C), confirming that APOBEC1 
plays a role in properly generating monocyte populations at various points during 
differentiation. Further experiments to catalog edited targets in cMOP cells are required 
to identify the mechanism through which editing modifies these progenitors. 
5.3. Editing is dispensable for initiating a strong inflammatory response 
Given that we observed preferential phagocytosis in vitro and creation of 
inflammatory-like monocytes in vivo, we speculated APOBEC1 editing could be 
involved in the establishment of the inflammatory response in general. To test this, I 
assayed the ability of wildtype and Apobec1-/- macrophages to respond to 
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lipopolysaccharide (LPS) and in vitro and in vivo. LPS is an endotoxin consisting of a 
lipid and a polysaccharide with an O-antigen, found in the outer layer of Gram-negative 
bacteria.  LPS binds to the CD14/TLR4/MD2 receptor complex in several immune cells 
including macrophages. This results in the production of pro-inflammatory cytokines, 
nitric oxide and eicosanoids. 
To test the ability of wildtype and Apobec1-/- BMDMs to mount an inflammatory 
response, I primed cells with IFNγ for 2 hours, followed by addition of LPS, and 
quantified the expression of APOBEC1 and several pro-inflammatory cytokines at 
several time points via qPCR. I also tested for the production of nitrogen reactive species, 
via the quantification of nitric oxide in the media after IFNγ + LPS stimulation. I 
observed that the expression of Apobec1 increased 2 fold after 18h of LPS stimulation 
and continued to increase over time (Figure 5.3.A). However, this was not accompanied 
by differential expression of Nos2, nor the pro-inflammatory cytokines Ccl5, Il12b or 
Il1a (not shown). The expression of the pro-inflammatory cytokine Tnfa seemed to be 
transiently induced at an early time point in Apobec1-/- BMDMs (Figure 5.3.B). 
To test whether there is differential production of cytokines, I performed a 
quantification assay using the Luminex technology. This consists of capturing free 
cytokines in the supernatant of the cell culture via beads coupled with specific antibodies. 
Next, these beads are incubated with fluorophores that aid in the determination of 
cytokine concentration. Luminex assays can be easily multiplexed, giving the ability to 
test for a large panel of cytokines at a time. I used the Cytokine 20-Plex Mouse Panel 
(Thermo Fisher Scientific), which includes a wide variety of cytokines as well as 
chemokines and growth factors (GM-CSF, IFN-γ, Il-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, 
Figure 5.3 | APOBEC1 deficient BMDMs do not have enhanced ability to 
establish an inflammatory response.  (A) Analysis of Apobec1  expression in 
wildtype  BMDMs after IFN + LPS stimulation, via qPCR (n=3). (B) Relative 
expression of Tnfa at different timepoints after stimulation with IFN + LPS. Both 
Apobec1  and Tnfa  were normalized using Rpl32.  (C)  Quantification of  TNFa 
protein in the supernatatnt of cells after 24 h of stimulation with IFNg + LPS (via 
Luminex; n=9). 
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IL-10, IL-12 (p40/p70), IL-13, IL-17, TNFα, IP-10, KC, MCP-1, MIG, MIP-1α, FGF-
basic and VEGF). Using this technology, I observed that there were no differences in the 
amount of cytokines secreted by Apobec1-/- BMDMs in comparison to their wildtype 
counterparts (e.g. TNFα is presented in Figure 5.3.C). Furthermore, I found that resting 
Apobec1-/- BMDMs did not express pro-inflammatory cytokines. 
Additionally, I tested the fitness of monocytes to incite an inflammatory response 
in vivo using two models of acute inflammation: intraperitoneal LPS and zymosan 
intraperitoneal injection. Both of these are particles found on bacterial outer membranes 
and yeast, respectively, and are identified by receptors in macrophages. Upon recognition 
of these particles, macrophages secrete inflammatory cytokines that are able to recruit 
more cells into the peritoneum. Depending on the dose utilized, the response can be 
cleared in 48 to 72 hours. I observed that wildtype and Apobec1-/- mice have a similar 
ability to induce an inflammatory response in the peritoneum: both mice have equal 
ability to recruit cells into the peritoneum, produce sufficient levels of inflammatory 
cytokines, and resolve the inflammation to allow for survival (data not shown). This is 
consistent with the in vitro results presented above. However, they seem inconsistent with 
the results that show a higher establishment of Ly6C+ pro-inflammatory monocytes in 
Apobec1-/-. 
This indicates that either there is no difference between the two genotypes, or that 
the time scale that I looked at is off. Another alternative is that the overwhelming amount 
of inflammation produced by the LPS and zymosan very highly activate the system and 
mask subtle differences. 
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5.4. Editing in microglia 
In an effort to continue with the characterization of inflammation in other organs, 
I collaborated with Dr. Karen Bulloch’s group at the Rockefeller University to study 
brain alterations∗. Dr. Bulloch’s group is interested in studying brain immunology and
brain pathologies in aging. They examined the brains of 3 month and 1-year-old wildtype 
and Apobec1-/- mice. They only identified alterations in the brains of aged Apobec1-/-. 
These alterations consisted of clustering of cells that stained positive for Iba-1 (a marker 
that in the brain is specific of microglia), indicative of activated microglia (not shown). 
This was accompanied by an increase in pro-inflammatory cytokine expression (from 
whole cortex and hippocampus extracts; not shown). 
In order to relate these findings to APOBEC1 editing, we first looked in the 
literature for gene expression datasets in brain cell subsets to identify cells expressing 
APOBEC1 within the brain. We examined the RNA-seq dataset from Zhang and 
collaborators102, who purified neurons, astrocytes, microglia, endothelial cells, pericytes, 
and various maturation states of oligodendrocytes from mouse cortex. We found the 
highest expression of APOBEC1 is within microglia and astrocytes. However, when we 
searched for the known APOBEC1 cofactors ACF and RBM47, we found that they were 
exclusively expressed in microglia, making this cell type the most likely candidate where 
editing might be found. These microglial cells were isolated from mouse brains using a 
two step approach, first brains were perfused with PBS in order to eliminate 
contaminating monocytes from the periphery, then microglia cells were isolated using 
∗	Dan	Cole,	Youngcheul	Chung,	Khatuba	Gagnidze	and	Karen	Bullock	
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CD45 antibodies. However, CD45 is a cell marker present in many subtypes of immune 
cells. Previous work from Dr. Bulloch’s lab, using a CD11c-egfp transgenic mouse, has 
demonstrated that mouse olfactory bulb CD45+ subset also includes brain dendritic cells, 
which can be characterized their expression of CD45 and CD11b, namely P1 (CD45int 
CD11bhi), P2 (CD45hi CD11bhi) and P3 (CD45hi CD11bint)103. Therefore, we sought to 
characterize the expression of APOBEC1 in two main subsets of CD45 expressing cells 
(CD45+CD11b+CD11c+ and CD45+CD11b+CD11c-) within cortex and hippocampus, 
where the brain alterations were originally described. 
In order to identify editing in these subsets, we first sorted CD45+CD11b+CD11c+ 
(CD11c+ MG) and CD45+CD11b+CD11c- (CD11c- MG) cells from wildtype and 
Apobec1-/- mice, and performed RNA extraction and library preparation to perform high 
throughput RNA-sequencing. Interestingly, using gene expression analysis, we did not 
find differential gene expression between wildtype and Apobec1-/- in either the CD11c+ 
MG or CD11c- MG subsets (not shown). This is very similar to my observations in 
BMDMs derived from the same genotypes (as mentioned in Chapter 2). 
In order to detect editing in the CD11c+ MG or CD11c- MG datasets, we used 
our editing detection algorithm. Surprisingly, the algorithms were only able to identify a 
few sites that were modestly edited. In order to validate these sites, I tested them through 
PCR amplification and Sanger sequencing, in a similar way as shown in figure 2.3; 
however, I could not validate any of the sites. 
I then decided to query the sites that were identified in BMDMs, to see if they 
could also be edited in the CD11c+ MG and CD11c- MG populations. To accomplish 
this, I looked at specific edited sites in several transcripts via PCR amplification and high 
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throughput sequencing (high throughput amplicon sequencing), which allowed me to 
access each site with substantially more depth than regular high throughput RNA-
sequencing. I chose several sites that are edited in BMDMs and expressed in the CD11c+ 
and CD11c- MGs (Table 5.2). Indeed I observed that the editing rate at these sites is very 
small in both populations of microglia, which is consistent with the failure of the 
algorithm to identify them. 
As I have posed before (in chapter 4), low levels of editing are not necessarily the 
representation of editing in single cells within a population. Given that editing is variable 
within BMDMs it is possible that it would also be within individual microglial cells. This 
would suggest that editing is not present in all microglia and that instead, subsets of the 
microglial population could exist which harbor high levels of editing. In order to test for 
this possibility, I examined a known subpopulation of CD11c+ cells that are 
characterized by the expression of the CD103 marker. These cells are highly enriched in 
olfactory bulb after intranasal infection with VSV103, therefore the cells were collected 
after VSV infection and RNA was extracted (this procedure was done previously for a 
project unrelated to this work). I used the RNA to do a spot check of editing in this 
population, amplifying two of the most highly edited targets in BMDMs, B2m and 
Lamp2, in a similar way as described for figure 2.3. I observed that in contrast to CD11c+ 
MG, which displayed a very small amount of editing, the subpopulation of 
CD11c+CD103+ cells had a high amount of editing (Figure 5.4). This shows that in fact 
different subpopulations of microglia demonstrate different levels of editing, therefore 
there is a possibility that the lack of APOBEC1 editing of a subset of cells may be 
involved in the clustering of microglia and inflammation phenotype observed in 
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Apobec1-/- aged brains. Further work is needed to identify the specific population(s) of 
microglia, which harbors APOBEC1 editing in aged brains, and to link those specific 
populations to the phenotype observed.  
Table	1a	|	Validated	edited	sites	in	column-separated	CD11c+	cells.	
UTR3 Anxa5 chr3 36449030 354443 1.40% 0.00% 72 2.80% 14530 0.1% 0.0%
UTR3 B2m chr2 122152613 91 1.10% 0.00% 31 0.00% 13468 1.6% 0.0%
UTR3 B2m chr2 122152682 452558 1.20% 0.00% 17854 0.60% 13680 0.0% 0.0%
UTR3 B2m chr2 122152740 444796 7.60% 0.00% 17223 5.70% 13627 0.2% 0.0%
UTR3 B2m chr2 122152742 446438 1.50% 0.10% 16235 1.00% 13628 0.1% 0.0%
UTR3 B2m chr2 122152787 669269 2.90% 0.20% 8190 1.40% 20889 0.3% 0.0%
UTR3 B2m chr2 122152804 675429 3.20% 0.00% 9610 1.90% 20914 0.3% 0.1%
UTR3 B2m chr2 122152902 416611 6.40% 0.00% 10425 3.90% 10358 1.0% 0.0%
UTR3 Lamp2 chrX 38421317 125796 1.00% 0.00% 666 0.50% 30059 0.0% 0.0%
UTR3 Lamp2 chrX 38421565 129390 1.30% 0.00% 893 2.00% 31356 0.0% 0.0%
UTR3 Sh3bgrl chrX 109160420 22804 4.10% 0.00% 16 12.50% 110353 0.0% 0.0%
UTR3 Sh3bgrl chrX 109160354 25647 3.90% 0.00% 23 0.00% 112949 0.0% 0.0%
UTR3 Sh3bgrl chrX 109160178 13610 2.10% 0.00% 18 0.00% 59802 2.0% 0.0%
UTR3 Dennd1b chr1 139175650 132688 1.60% 0.00% 5 0.00% 52069 0.0% 0.0%
exonic Med13l chr5 118754418 163564 1.10% 0.00% 39 0.00% 70500 0.0% 0.0%
exonic Pki3r4 chr9 105650713 2585 1.30% 0.00% 12 0.00% 1 0.0% 0.0%
Amplicon	sequencing	was	also	performed	in	9	other	genes	with	no	editing	detected	(Sec24a,	Rapgef5,	Tfrc,	Semad6,	Psmc3ip,	Zfp318,	Dnajc1,	Dcun1d4	and	Gab2).	
Table	1b	|	Validated	edited	sites	in	column-separated	CD11c-	cells.	
UTR3 Anxa5 chr3 36449225 84085 1.80% 0.00% 256 0.00% 15824 0.0% 0.0%
UTR3 Anxa5 chr3 36449030 78293 1.50% 0.00% 120 0.00% 14530 0.1% 0.0%
UTR3 B2m chr2 122152902 180151 7.30% 0.00% 9715 4.80% 10358 1.0% 0.0%
UTR3 B2m chr2 122152740 192034 5.90% 0.00% 15585 6.80% 13627 0.2% 0.0%
UTR3 B2m chr2 122152804 282971 3.40% 0.20% 7405 2.70% 20914 0.3% 0.1%
UTR3 B2m chr2 122152787 283924 2.30% 0.10% 6187 2.10% 20889 0.3% 0.0%
UTR3 B2m chr2 122152742 193011 1.40% 0.00% 14523 1.50% 13628 0.1% 0.0%
UTR3 B2m chr2 122152682 195676 1.30% 0.00% 16883 0.90% 13680 0.0% 0.0%
UTR3 B2m chr2 122152871 177490 1.10% 0.00% 5569 0.90% 19000 0.2% 0.2%
UTR3 Lamp2 chrX 38421565 23541 1.70% 0.00% 1041 0.90% 31356 0.0% 0.0%
UTR3 Lamp2 chrX 38421618 23633 1.10% 0.00% 1649 0.10% 31379 0.0% 0.0%
UTR3 Lamp2 chrX 38421317 20690 1.10% 0.00% 751 0.80% 30059 0.0% 0.0%
UTR3 Rac1 chr5 143505935 97069 1.60% 0.00% 365 0.80% 1208 0.6% 0.0%
UTR3 Jag1 chr2 137081857 122649 2.00% 0.00% 0 nan 24 4.2% 0.0%
Amplicon	sequencing	was	also	performed	in	14	other	genes	with	no	editing	detected	(Cluh,	Polrmt,	Fut8,	Alg12,	Enpp1,	Lpp,	Sepn1,	Vamp4,	Bms1,	D7ertd443e,	Usp48,	Socs4,	
Ncapd3	and	Mast2).	
RNA	-sequencing Amplicon	sequencing	on	DNA
Reads	
Coverage
Frequency	
of	C	to	T	
Frequency	of	
Non-C	to	T
Reads	
Coverage
Frequency	
of	C	to	T
Reads	
Coverage
Frequency	
of	C	to	T	
Frequency	of	
Non-C	to	T	
Region Gene Chromosome Coordinate
Amplicon	sequencing	on	cDNA
Frequency	of	
Non-C	to	T	
Amplicon	sequencing	on	DNA
Region Gene Chromosome Coordinate Reads	
Coverage
Frequency	
of	C	to	T
Reads	
Coverage
Frequency	
of	C	to	T	
Frequency	of	
Non-C	to	T
Amplicon	sequencing	on	cDNA RNA	-sequencing
Reads	
Coverage
Frequency	
of	C	to	T	
Table 5.2 | Amplicon sequencing-based validation of putative edited genes. 
Sites found in BMDM were amplified in both CD11c+ and CD11c- MG and 
sequenced and the frequency of C to T changes was quantified. 
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AB
B2m 3’UTR
Reference seq.
Subclones
T
T
T
T
T
T
T
T
T
T
T
T TT
T T
T
T
T
T
T
T T
T
T
T T
T
T
T
T
T
T
T
T T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T T
T
T
TTACAAATCCAGTTTCTAATATGCTATACATTTATGCACGCAGAAGAATAGCAATGTACACATCACCTTCTTTATATCTTACTTTAAATATTTATGCATGTTTTCAAAATTGGAAATATCCTAGATAGCTGAGCAATAAATCTTCAATAAGTATTTTGATCAGATAATAATATAATTTTAAGACATAGTTGATCATATGCCAACCCATCTGTACTTC
Lamp2 3’UTR
Reference seq.
Subclones
G
G
T
G
G
T
T
T
T T
N
AAACAAAAGAATTCCAAATACTATCAACTACAAATGAATCATATGATTTTGGTTTTCCTGACTAAGGAGTTTAAAATTACTATGGCAAAAGGCATGTACAAAATTATCTGGTTCT // TCCTTTTGCATTGCTTGTGACTTTTTGTTTGCAGGTTGACTTAGCTACTTCGGCCTTGTTCCATATTTGACCTATTGA
Figure  5.4  |  APOBEC1  editing  is  present  in  a  subset  of  microglial  cells 
characterized by CD11c+ CD103+ expression. C to T RNA editing events can 
be seen in the B2M (A) and Lamp2 (B) transcripts of subclones obtained from 
CD45intCd11b+EYFP+ cells from Cd11c-EYFP mice.	
70
71	
CHAPTER 6. DISCUSSION 
At the beginning of my work, the role of Apobec1, except for a couple of 
exceptions, seemed to be constrained to the intestine and exquisitely confined to lipid 
transport and metabolism through editing of the ApoB transcript. With the advent of high 
throughput sequencing technologies, our group was able to identify additional targets of 
Apobec1 within the intestine and in several cells of the immune system, especially in 
macrophages. However, the significance of these findings was absent, as were the 
functional consequences of these modifications.  This is a common theme for ADAR 
targets as well, since for most such transcripts, especially the ones that do not result in 
changes in coding regions, the functional consequences remain murky. 
Upon close examination of APOBEC1 targeted transcripts I was able to 
demonstrate that Apobec1 editing has a significant role outside of the intestine as it 
confers macrophages the ability to maintain proper homeostasis.  These results were 
presented throughout my thesis and will be discussed in depth here. 
6.1. Comparison of wildtype vs. Apobec1-/- macrophages 
My experiments demonstrated that although there are no differences in transcript 
processing (transport, stability and differential expression) between the wildtype and 
Apobec1-/- genotypes, APOBEC1 regulates protein expression in miRNA dependent and 
independent ways, which are the direct consequence of editing. As noted in figures 3.1.1 
and 3.1.2, Apobec1 edited transcripts did not display selective nuclear retention, in 
comparison to their unedited counterparts. This is a process that for ADAR, has been 
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proposed to be a molecular consequence of editing, which is mediated through binding of 
an RNA binding protein (p54), which presumably recognizes the tertiary structure of he 
dsRNA. In the case of Apobec1 editing, we do not expect edited regions to have specific 
tertiary structures due to their AU rich nature. However, differential RNA protein binding 
between edited and unedited transcripts is still to be investigated. 
Stabilization of transcripts is the second process that has been proposed for 
ADAR editing, therefore I decided to test whether this is a general phenomenon that 
results from editing. Also, Apobec1, in its role as an RNA binding protein, has been 
shown to increase the stability of several transcripts with AU rich 3’UTRs, such as COX2 
and TNF-α. Figure 3.1.3 shows that Apobec1 edited mRNAs have a high stability, even 
when Apobec1 is absent from the milieu (in the Apobec1-/- sample). This indicates that 
perhaps Apobec1 transcript stabilization is separate form its role in editing.  
I also showed a significant overlap between Argonaute occupancy and APOBEC1 
target regions (not shown), and that in principle, the change in a single nucleotide within 
the miRNA-binding site has the ability to modify miRNA binding (Figure 3.2.2). This 
agrees with what has been found for ADAR edited miRNAs49,104. This is significant 
because editing of miRNAs results in stringent and tissue-specific gene regulation, which 
is crucial for development. By editing miRNA target sites, a shift or redirection of target 
genes could be created, given that the pool of miRNA increases. This is yet to be 
investigated for both Apobec1 and ADAR editing. Further discussion on miRNA 
detection and regulation is presented on chapter 7.3. 
During the course of my work, Davidson’s group at the University of Washington 
also examined the transcripts of liver and intestine of wildtype and Apobec1-/- mice, and 
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observed that in those systems, editing also results in altered protein expression105. His 
group conducted differential gene expression analysis, and in contrast to my data, he 
found that a few hundred genes were differentially expressed between wildtype and 
Apobec1-/- enterocytes. Among those, 17 edited genes were differentially expressed. 
Furthermore, using SILAC (method discussed in section 3.3) they were able to find 26 
edited genes differentially translated with a magnitude of two fold changes. This agrees 
with what I have reported in figures 3.3.1 and 3.3.2A, and points to a conserved function 
of Apobec1. They also showed differences in expression of CD36, which agrees with my 
findings, presented on figure 3.3.1B. However, when I analyzed translation globally via 
ribo-seq (method discussed in section 3.3) I didn’t observe significant differences 
between the wildtype and Apobec1-/- genotypes. This could be an inherent difference 
between the two systems: enterocytes vs. macrophages. Alternatively, it could be that the 
changes in protein expression I observe in Cd36, for example, are result of an alternative 
mechanism, such as ribosome stalling. Caveats on ribo-seq method are further discussed 
on section 6.3, below. Blanc and collaborators, however, did not explore further the 
implication of the observed protein changes in enterocyte biology. 
Altogether, changes in protein expression have implications for the fine-tuning of 
macrophage responses to changing environments. Previous investigations of the 
functional consequences of RNA editing have focused on instances where transcripts are 
edited with very high frequency and/or alter decoding by targeting genic sequences, 
which makes them have clear biological implications (e.g. APOBEC1 editing of 
Apolipoprotein B58 and ADAR editing of GluR96,97).  However, the collective functional 
consequence of targeting a large number of transcripts has never been examined, and is a 
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long standing question in the field. One of the challenges of such an analysis is the low 
frequency of editing in the vast majority of sites. Altogether the frequency of APOBEC1 
editing and the resulting changes in protein expression we have found in BMDMs are 
modest. We hypothesized that these small changes would not be sufficient to have 
biological consequences by themselves. However, it is possible that the sum of small 
changes in a certain pathway or function would make an important contribution to the 
resulting activity. 
 Indeed, when I looked closely at two of the most important activities of 
macrophages, migration and phagocytosis, I discovered that cells from the two 
phenotypes are indeed not equivalent (figure 5.1). In the case of phagocytosis, I found 
that editing targets several structural proteins that are essential for the formation of the 
mature lysosome, as well as proteins involved in the formation of proton pumps, also 
necessary for the acidification of the phagosome. Furthermore, some other proteins, 
which were not specifically identified to be in the same pathway through literature 
mining, but are nevertheless necessary for uptake of particles, such as cytoskeleton 
remodeling proteins and a scavenger receptor, are also edited. 
Neither of the above mentioned proteins would represent a good candidate for 
further studies on their own due to the low fraction of edited transcripts at the population 
level. Therefore, new strategies would need to be devised in order to dissect the exact 
contribution of each one of them to the overall phenotype. This may involve examination 
at the single cell level, where I demonstrate variability in terms of editing exists among 
cells of the same genotype (in figures 4.2.3 and 4.3.1). In such a scenario, a target that is 
edited at a low frequency in the population could be highly edited in just a subset of cells, 
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in which the consequences of editing would be magnified. For example, let’s take the 
case of migration, where Apobec1-/- macrophages seem to be unfit to migrate whereas 
their wildtype counterparts do so quite efficiently (figure 5.1): if we were to look at a 
subset of macrophages that migrate more efficiently and therefore cross the membrane 
first, we might find that they posses a particular editing signature that is different from 
the macrophages that migrate at a slower pace. This kind of study would be relevant 
because low frequency editing is actually quite pervasive, especially in the case of ADAR 
editing, and insights from this work may be applicable to other scenarios, such as the 
brain. Additionally, given that other epitranscriptomic marks have such a dynamic nature, 
I expect that the study of the sum of editing events, C to U as well as A to I, will uncover 
a wonderfully complex regulatory network.   
Furthermore, macrophages have the characteristic that they are very plastic, that 
is, they are able to change their phenotype in response to varying environmental cues. 
Here, I provide two key findings that have implications in macrophage plasticity and may 
contribute to heterogeneity in cells that appear identical (as defined by gene expression 
measurements): (1) Editing is variable between cells from a seemingly homogeneous 
population (as shown in figures 4.2.3 and 4.3.1), and (2) Apobec1-/- monocyte 
differentiation is altered in the absence of editing (as shown in figure 5.2.2). These results 
indicate that perhaps editing is involved in the formation of subsets of cells with different 
capabilities, some of which are perhaps better equipped for specific environments and 
may act as “first responders” that eventually signal to the rest of the population in order 
to create a coordinated response. This possibility needs further investigation but it is a 
very enticing hypothesis. 
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Altogether these results predict alterations in the monocyte population in 
Apobec1-deficient mice that might result in physiological alterations in the mice. Indeed 
this is the case in brains of aged mice, where our collaborators found alterations in the 
distribution of microglia, accompanied with inflammation (which under normal 
conditions is absent in the brain). Even though I did not provide direct evidence that 
editing is involved in creating this phenotype, I do believe that there is a connection. If 
editing is indeed creating subpopulations of cells that have “special” characteristics, such 
a subset in the context of the brain may be playing a modulating role, in charge to 
maintain homeostasis, preventing unnecessary inflammation. A finer characterization of 
the heterogeneity of microglia within the cell would be necessary to test for this 
hypothesis and conditional deletion of APOBEC1 within this subpopulation would be 
necessary in order to directly link editing to the phenotypes observed. 
However, the consequences of APOBEC1 deficiency in the brain do affect the 
mice significantly. Further research from our collaborators at Dr. Bulloch’s lab found that 
these physiological changes are accompanied by alterations in mouse behavior (personal 
communication), which highlights the importance of APOBEC1 in modulating 
homeostasis. The work of our collaborators is likely to be key in recognizing 
physiological alterations in the Apobec1-/- mice, and in establishing a link between 
APOBEC1 editing and brain disorders. 
6.2. Caveats on the molecular characterization at the RNA level 
At a first glance we may conclude, upon examination at the molecular level, that 
the function of APOBEC1 can be attributed to the modulation at the protein level, and 
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that the transcripts affected undergo no alternative fates than their unedited counterparts. 
That is, edited and unedited transcripts are equivalent to the cell. However, Davidson and 
collaborators have reported differential expression between the two genotypes in 
intestine, which also leads to differential translation of edited transcripts105. This 
discrepancy may be a reflection of the different cell systems used: enterocytes vs. 
macrophages. But the possibility still exists that true differences are being obscured due 
to the fact that Apobec1 does not edit with 100% efficiency at every site. Therefore, the 
currently available genome-wide comparison is of a true editing deficient (Apobec1-/-) to 
an almost deficient (wildtype) counterpart. This is indeed one of the major obstacles with 
the gene expression, stability and localization measurements and in general, to the 
complete molecular characterization of edited transcripts. 
Such characterization is possible, using for example the constructs like the ones 
employed here for luciferase assays. However, this kind of assay would be cumbersome 
and low throughput. A better approach would entail the analysis of both edited and 
unedited transcripts within the wildtype sample. Such an experiment would have the 
added advantage that both transcripts are subjected to the same milieu and have as similar 
availability to the same RNA binding proteins as possible. Current technology does not 
allow for such an experiment. However, one of the ways in which I envision one could 
tackle this problem is through selective tagging of edited transcripts either via 
complementation with fluorescent probes, or alternatively, by engineering an APOBEC1 
enzyme that is fused to a protein that adds an additional tag (e.g. a methyl mark) to 
APOBEC1 bound (and thus presumably edited) transcripts. Such marked transcripts 
could then be separated and quantified (at different time points for stability or in the 
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different fractions) or sequenced independently from the untagged (and presumably 
unedited) ones (Figure 6.2, below). 
A second option is to engineer an APOBEC1 enzyme that is capable of editing 
each transcript 100%, which would be informative for fine molecular characterization of 
transcript expression differences and protein production. However, it would not allow us 
to see what biological consequences are truly the results of fine-tuning. Moreover, it 
would eliminate the cell diversity created by hyperediting, which in its complexity may 
Figure 6.2 | Proposed methodology to follow edited and unedited transcripts 
within the wildtype sample. (A) A modified Apobec1-tagging protein fusion will 
both edit and tag transcripts during transcription. Cells that express this fusion 
protein can also be treated with Actinomycin D for stability measurements or any 
other substance of interest, for example, LPS. (B) RNA from those cells can be 
retrieved and edited transcripts separated from the pool via any method that is 
best for selecting the specific tag on the RNA (e.g. immunoprecipitation (IP),  
column separation, etc.). Once the fractions have been separated, gene expression 
analysis can be performed.
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be the core of APOBEC1 editing, whatever that may be. The main caveat of engineering 
a protein that has 100% efficiency is that it could have off target effects, such as DNA 
editing. It has been reported that Apobec1 (especially of rat origin) can induce DNA 
mutations and promote cancer106,107. In a study by Severi and colleagues, rat Apobec1 was 
shown to target a GFP reporter inserted into DT40 chicken cells107, which inactivates 
expression of GFP, a system used to extensively analyze AID-mediated DNA editing108. 
They found that the mutational signature of APOBEC1 resembles that of AID. 
Furthermore, they demonstrated that a similar process happens in K562 human cells (a 
model of chronic myeloid leukemia), whose mutational sequence context resembles that 
of esophageal adenocarcinomas. This shows that off target effects can be related to the 
level of expression of Apobec1. It has been proposed that the limiting factor preventing 
high amounts of APOBEC1-mediated ApoB editing is the amount of ACF, which acts as 
a repressor of Apobec1. This could also be the case of overexpression of Apobec1 
leading to DNA methylation, albeit not necessarily through ACF.  
One possibility that could be examined is whether APOBEC1 contributes itself to 
the stability of transcripts. It has been previously reported that APOBEC1 has affinity for 
AU rich sites that have been shown to be present in several untranslated regions of 
transcripts which are known to undergo fast degradation70. Upon APOBEC1 binding, the 
half-life of such transcripts apparently increases. Given that the transcripts affected by 
APOBEC1 in macrophages are also AU rich, the possibility that APOBEC1 itself and not 
only the editing is responsible for the long half-life still remains to be examined. In order 
to test for this, Apobec1 conditional mutants would need to be constructed. One of the 
main obstacles for this is the lack of knowledge of the crucial residues necessary for 
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editing. A report by MacGinnie et. al. identified several residues responsible for Apobec1 
editing of ApoB through mutational analysis. They found that a histidine to arginine 
(H61R) yielded a catalytically dead enzyme and glutamic acid to glycine (E63G) resulted 
in binding but not editing of ApoB mRNA in vitro109. However, when we tested whether 
these mutations would eliminate editing of Apobec1 targets in macrophage, we found 
that both mutations resulted in editing.    
6.3. Caveats on the molecular characterization at the protein level 
The extent to which protein regulation by APOBEC1 editing is the result of 
miRNA binding still needs to be further investigated. We identified 19 transcripts in 
which there were sites that could be created or destroyed, but there were further miRNA 
binding sites contained within the footprints that were seemingly unaffected. However, 
we estimate that a larger number of binding sites may be targeted in the cases where 
hyperediting is pervasive. In these cases, the complexity of the possible combinations 
makes it difficult to estimate the specific contribution of editing at any site, including 
sites relevant to microRNA regulation. 
The binding of Argonaute and mature mRNA-miRNA complexes leads to their 
interaction with the RISC complex, which in turn leads to gene inhibition via three main 
mechanisms: site-specific cleavage, mRNA degradation and translational inhibition. Both 
site-specific cleavage and mRNA degradation would result in differences, albeit small, in 
gene expression110,111. The latter of the processes occurs commonly in mammals and is 
established when the decrease in protein production is greater than the reduction in the 
corresponding mRNA levels112. Given that we have not been able to observe differences 
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in gene expression or stability in transcripts derived from wildtype vs. Apobec1-/-, we 
speculate that the process editing is involved is in translational repression.  The 
mechanism for this type of repression is not yet fully understood, but several models have 
been proposed to induce repression at several different stages of translation, including 
initiation113–117, increased premature termination118 and impaired elongation112. 
Furthermore, it has been reported that Ago2 binds directly to the m7G-cap of the mRNA 
preventing translation initiation119. We speculate that any of these mechanisms is 
responsible for the miRNA regulation. However, the analysis of whether any one or 
several of these mechanisms is involved in the APOBEC1-mediated protein regulation is 
still to be investigated. 
Given that the vast majority of edited transcripts are not predicted to contain a 
miRNA binding site or have one created or destroyed by editing, we decided to consider 
whether regulation was also possible for these transcripts. We observed through 
luciferase assays, where the 3’UTRs of edited transcripts were fused to the luciferase 
reporter, that miRNA independent regulation is also possible. Interestingly, this is also 
the case for a subset of transcripts, most notably the ones that are hyperedited. A finer 
dissection of which site or sites are the most important for this regulation is still to be 
performed. Additionally, it does appear that a higher frequency of hyperediting correlates 
with higher protein repression. However, in the case of the hyperedited transcripts B2m 
and Lamp1, we were unable to see differences in endogenous protein levels. We 
speculate that if only a subset of edited transcripts is responsible for the repression of 
protein, it could get lost in the bulk analysis. This underscores the importance of analysis 
of single cells, which would be able to show whether for a subset of cells that are 
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enriched for a certain type of hyperedited transcripts, we would be able to see differences 
in the endogenous expression of such proteins. We believe this might be the case because 
we also found a special example (CD36) where the regulation shown in the luciferase 
assays is also present in the endogenous protein levels. 
Differential ribosomal binding of a subset of Apobec1 edited transcripts was 
recently reported105, corroborating my luciferase results (Figure 3.3.1).  However, when 
we looked globally at the translational output through sequencing of the polyribosome-
bound fraction, we observed only subtle differences between the translation of edited 
genes between wildtype and Apobec1-/-. This is not completely unexpected because thus 
far, we have not observed big changes except for the case of CD36. 
Some of the caveats of Ribo-seq are that it is unable to distinguish stalled 
ribosomes or for transcripts that are translated with higher or lower efficiency, or those 
which are stalled120,121, due to its lack of temporal information. For example, there are 
higher amounts of native CD36 protein in Apobec1-/- BMDMs, but its transcript is not 
one of the highest differentially ribosome-bound. It is possible that this transcript is one 
such example of an efficiently translated transcript. Given that the differences we observe 
are subtle, a temporal analysis would be helpful to determine whether editing has a role in 
either stalling or translation efficiency. The latter is a process that is highly dependent on 
the 3’UTR length122 and binding factors123–125, whose interaction with the 3’UTR could be 
inhibited by editing.  
Furthermore, Apobec1 editing events cannot be observed in the ribosome 
footprints, as the footprints only cover the coding region of transcripts and editing events 
are almost exclusively located in the 3’UTR. In order to test whether edited transcripts 
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are equally able to bind ribosomes, the proportion of edited transcripts in total vs. 
ribosome-bound RNA should be quantified. In order to do this, I devised an experiment 
involving an alternative ribosome capture technology, called translating ribosome affinity 
purification (TRAP)-seq126. TRAP-seq takes advantage of Ribosomes tagged with a GFP 
tag for purification of the ribosome bound fraction. In the published method, the RNA is 
collected and ribosomes are immunoprecipitated using GFP-specific antibodies and 
stringently washed. After ribosome pool down, the entire transcripts are available and 
library preparation for direct RNA sequencing of both fractions is possible. For the 
detection of editing, I propose to perform amplicon sequencing of the RNA in both the 
pool down tagged ribosome and whole RNA fractions, using a similar method as 
described in section 4.3, which uses molecular tagging of transcripts (see figure 6.3.1 
below). I believe this method would give a unique insight into the mechanism by which 
edited transcripts are translated, that could explain the luciferase results presented in 
Figure 3.3.1 (see figure 6.3.2 below).  
6.4. Steady state versus activated macrophages 
This work provides an overview of the possible functions of APOBEC1 in 
macrophage biology. However, these studies are a mix of steady state and activated 
macrophages. I characterized the edited sites in steady state BMDMs, and showed that 
these cells gave rise to altered phagocytosis and migration; and I showed that Apobec1 
could get induced after LPS stimulation. Therefore, it is important moving forward to 
characterize how editing is altered during the activation of cells, which could give insight 
into Apobec1 function during an inflammatory response and would clue us into which 
Figure 6.3.1 | Modified TRAP-seq method to identify ribosome-bound edited 
transcripts.  Depicted  are  the  possible  method  for  detecting  editing  within 
ribosome-bound transcripts. Using GFP tagged ribosomes, the fraction of RNA 
being translated can be isolated from the untranslated part. Reverse transcription 
with barcoded primers can help identify individual RNA molecules after PCR 
amplification. Finally, the PCR amplicons can be used for library preparation and 
high throughput sequencing. 
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Figure 6.3.2 | Scenarios that would explain differences in protein expression. 
Depicted  are  the  possible  explanations  that  would  result  in  the  differences 
between wildtype and Apobec1-/- genotypes shown via luciferase, from looking 
at the different scenarios of ribosome binding. 
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aspect of inflammation is being involved, given that the experiments currently available 
are inconclusive (figure 5.3).  
On the other hand, we unexpectedly encountered that APOBEC1 may play a role 
in monocyte differentiation. Macrophages are a heterogeneous population of cells that 
have, for research purposes, been classified into different categories given their activation 
and differentiation states. Even though BMDMs are an excellent model for the study of 
macrophage responses, they do not represent the functional state of most monocyte 
populations in vivo. The closest relatives of BMDMs in vivo are fully differentiated 
tissue-resident macrophages. Therefore, many of the observations from the in vitro 
studies may or may not apply to these populations. Edited sites within the MDP, cMOP 
and Ly6+ and – populations remain to be determined. These could shed some light into 
the role of Apobec1 in the differentiation and also, into which compensatory mechanisms 
are in place for normal development vs. ones that have developed after grafting. 
It is important to consider also that the cells derived from grafting develop in an 
inflammatory environment that is the result of whole body irradiation. It is possible that 
the two environments are not equivalent and that Apobec1 only plays a crucial role when 
cells are exposed to certain inflammatory environments. If this were the case, it would be 
relevant for the observations in aged brains, where there is an established inflammatory 
environment. It would also help shed light on the mechanism by which the phenotype of 
clustered microglia and inflammation in Apobec1-/- aged brains arises: activated 
microglia provided a pro-inflammatory environment that results in degradation of 
neurons; or inflammation from some other origin activates otherwise normal microglia 
and initiated the brain alterations. If inflammation leads to Apobec1 expression (as shown 
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in figure 5.3) and Apobec1 is involved in the regulation of monocytic cells under 
inflammatory conditions (as shown in figure 5.2.2), it is possible that the underlying 
mechanism of Apobec1 is the regulation (through editing or indirectly) of genes that 
maintain the monocyte program. This could be a potential mechanism underlying the 
aberrant activation of microglia in the brain of Apobec1-deficient mice: they lack 
adaptability to the inflammatory environment due to APOBEC1 loss.  
6.5 Closing remarks 
The substantial phenotypic diversity of monocytes is established epigenetically, 
and maintained by local environmental cues. Hence, discrete monocyte subsets have 
unique transcriptomic signatures. However, phenotypic heterogeneity is also present 
within specific subsets with identical transcriptomic signatures. Here, I demonstrate that 
APOBEC1-mediated RNA editing generates sequence heterogeneity in macrophages that 
appear identical by gene expression measures, but which nevertheless can show 
phenotypic differences. 
These epitranscriptomic sequence changes occur mostly in transcript 3' 
untranslated regions (UTRs) and result in alterations in the quantity of individual proteins 
through a variety of mechanisms, including miRNA target sequence ablation. The data 
presented here constitutes the first instance where RNA editing of clusters of transcripts 
that aggregate in common pathways is shown to specifically affect the output of those 
pathways, and by extension, cell physiology. 
My work suggests that the sequence diversity contributed by RNA editing might 
provide subsets of cells with distinct informational content. Further, our work implies that 
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RNA editing might underlie or anticipate the functional heterogeneity apparent in 
populations of cells of monocytes, the mechanism for which is currently not understood. 
The data also suggests that editing may contribute to the substantial phenotypic diversity 
of monocytes, such that phenotypic heterogeneity is also present within specific subsets 
with identical transcriptomic signatures. 
I also demonstrate that changes in protein abundance initiated by RNA editing 
have functional consequences for the physiology of the monocytes, both in vitro and in 
vivo, predicting that slight differences in the maintenance of monocyte subsets might, 
over time, have critical consequences for the health of the organism. 
Given that standard genome-wide association studies (which catalog DNA 
changes) have not been particularly successful in predicting disease progression or 
manifestations of neurodegenerative or psychiatric disorders, the development of a link 
between aberrant RNA editing and brain disorders, might be useful for identifying 
signatures, shared with peripheral monocytes, that can be used in diagnosis, prevention or 
treatment. 
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CHAPTER 7. METHODS 
7.1. Mice and isolation of BMDMs 
C57BL6 littermate or age-matched mice were used at 6-12 weeks of age. 
Apobec1-/- mice were a gift from N.O. Davidson (Washington University School of 
Medicine). Mouse femurs were removed and flushed with cold PBS onto a cell strainer. 
Precursor cells were plated onto untreated 10cm dishes and incubated in a humidified 
37°C, 5% CO2 incubator for 7 days in DMEM, 10% FBS 1% Non-essential amino acids 
(Invitrogen), 0.1% BME, 20ng/mL M-CSF (Peprotech), replacing half of the media (with 
complete media plus 40ng/mL M-CSF) every 3 days. Macrophage surface markers: 
F4/80 (Invitrogen) and Cd11b (BD biosciences) were confirmed via flow cytometry on a 
FACS Calibur flow cytometer after the 7-day maturation. 
7.2. mRNA-Seq 
RNA was extracted from macrophage cultures using the Ribopure kit (Ambien). 
DNAse treatment was performed with Turbo DNAse (Ambien). mRNA libraries for 
Illumina sequencing were prepared as previously described82 with the following 
modifications: 1) polyA selection was performed with Sera Mag oligo-dT magnetic beads 
(Thermo) 2) mRNA fragmentation in fragmentation buffer was adjusted for higher read 
length, and was performed for exactly 4 min 45s 3) After double-stranded cDNA libraries 
were separated by agarose gel electrophoresis and fragments ranging from 275-325nt 
were excised. Single-end 75nt sequencing was performed on Illumina Genome Analyzer 
IIx (GAIIx) yielding 28-33 million reads. Trimmed reads were mapped to the C57LBL/6 
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mouse reference genome (NCBI37/mm9) using Tophat (v1.3.3) and Bowtie (v0.12.8) 
with the tophat parameters “--solexa1.3-quals -g 1 --coverage-search.” Gene expression 
levels were calculated using Cufflinks (v1.2.1) using the Ensembl gene set. 
7.3. RNA editing detection pipeline 
A vector consisting of the number of A’s, T’s, G’s and C’s that occurred at each 
coordinate were constructed from the SAMtools pileup33 for both the wildtype and 
Apobec1-/- bulk RNA-seq alignments that were de-duplicated using Picard 
(http://broadinstitute.github.io/picard). For each coordinate that exhibited a C-to-T 
change only in the wildtype sample (that is, not in the knockout alignment, such that only 
APOBEC1-dependent C-to-T changes are kept) and met a number of stringent quality 
control thresholds (minimum of five reads covering site, with at least two reads 
supporting the editing event, excluding sites that showed multiple types of transitions; 
and discarding reads that contain indels, support an edit in the first or last two base pairs 
of a read), the angle between the corresponding vectors for the wildtype and Apobec1-/- 
were compared. Putative hits were retained if the magnitude of the wildtype vector was at 
least 15 and the angle between the wildtype and Apobec1-/- vectors was at least 0.11 
radians (approximately equivalent to a minimum coverage of 20 reads and an editing rate 
of 10%). Potential sites were also filtered against genomic DNA-derived SNPs 
indbSNP138, and removed if they occurred within four base pairs of a splice junction 
(using the exon junctions compiled by the Zhang lab, using OLego34) or in simple or 
tandem repeats (softmasked regions by RepeatMasker). Reads supporting edits were run 
through BLAT35 to ensure that they were not ambiguously mapped. The pipeline was 
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programmed using Bash and Python with the Pysam (https://github.com/pysam-
developers/pysam) pileup engine. RNA editing events were then validated by designing 
primers proximal to the sites of interest, amplifying those regions from cDNA and 
genomic DNA from both wildtype and Apobec1-/- cells, and performing colony 
sequencing. 
7.4. Subcellular fractionation 
A total of 10x106 bone marrow derived macrophages were resuspended in 
200μL of cold cytoplasmic buffer (0.15% NP-40, 10mM Tris pH 7.5 and150mM NaCl) 
and incubated on ice 5 minutes, in order to break the cell membrane. The nuclei were 
separated by centrifugation at 16,000 rcf, 10 minutes at 4ºC. The cytoplasmic supernatant 
was separated and the nuclei pellet was washed twice with cold PBS. The nuclei were 
gently resuspended in 100μL of glycerol buffer (20 mM Tris pH 8, 75 mM NaCl, 0.5 mM 
EDTA and 50% Glycerol). Next, 100μl of nuclei lysis buffer (20 mM HEPES pH7.6, 7.5 
mM MgCl2, 0.2 mM EDTA, 0.3M NaCl, 1M Urea, 1% NP40) were added and lysed by 
vortexing twice for 2 seconds and incubating 2 minutes at 4C. The chromatin fraction 
was separated with a spin at maximum speed, 2 minutes at 4C. Total RNA was separated 
from both the nuclear and cytoplasmic fractions using phenol chloroform isoamyl alcohol 
extraction. The fractionation efficiency was determined by western blot using alpha 
tubulin (Sigma 4500088) and H3K27Me3 antibodies (Abcam 6002).  
RNA half-life estimates after exposure to actinomycin-D. 
Cultures of BMDM were exposed to actinomycin-D at a concentration of 
10μg/mL for periods of 0, 0.5, 1, 2 and 5 hours. RNA was collected via Trizol and 
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reverse transcribed using Superscript III and polydT primers. The concentration of edited 
genes Cybb, Sptssa, App, Cd36, Lamp1, Lamp2 and B2m was determined by RT-PCR, 
normalizing to GAPDH. Additionally, the genes Atp5a1 and Jun were measured by RT-
PCR as controls for long and short-lived transcripts in macrophages, respectively. The 
half-life of the transcripts was calculated using the formula t1/2= ln(2)/kdecay, where kdecay is 
the slope of a semilogarithmic plot of the concentration of mRNA in time.  
7.5. HITS-CLIP analysis 
Argonaute HITS-CLIP was performed in conjunction with the Darnell lab as 
previously described84, with a few modifications: BMDMs were isolated from 3 wildtype 
and Apobec1-/- littermate pairs. BMDMs were matured as described above and 
crosslinked 3x at 200mJ/cm2 in 3mL of 1xPBS on a bed of ice. BMDMs were scrapped 
off the plates, flash-frozen and stored at -80C. Frozen cells were thawed and lysed in 
1mL PXL lysis buffer (1x PBS, 0.1% SDS, 0.5% Na-DOC, 0.5% NP-40) with complete 
protease inhibitor. Cells were DNAse treated with RQ1 RNAse-free DNAse (Promega). 
RNAse treatment performed with high (1:100) or low (1:10,000) RNAse A solutions.  
Protein A beads (first loaded with rabbit anti-mouse IgG bridging antibody (Jackson 
ImmunoResearch, at 2.3 mg/mL)) were then incubated with 3 uL Ago antibody (2A8 
ascites provided by Dr. Z. Mourelatos) per 400 uL of beads and rotated for 3 hours at 
4°C. Lysates were incubated with primary antibody-loaded beads for 2 hours at 4°C and 
washed in a series of high- and low- stringency washes, after which 5'phosphate 
dephosphorylation was performed, and a radiolabeled linker was ligated to the 3'end of 
the bound RNA species. Cold L32 RNA linker with 5’ phosphate was added to this 
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mixture after 1 hr and it was incubated overnight and washed 3x with PNK buffer. 5’ 
ends were re-phosphorylated with T4 PNK. Protein:RNA complexes were eluted off the 
beads in NuPAGE loading buffer (Invitrogen) and supernatants were run on Novex 
NuPAGE 8% Bis-Tris gels (Invitrogen) in MOPS running buffer (Invitrogen), transferred 
onto Protran BA85 nitrocellulose (Whatman) and exposed to Biomax MR film (Kodak). 
Regions that corresponded to Ago:mRNA and Ago:miRNA complexes were 
excised from the membrane and treated with proteinase K (4mg/mL Roche). RNA was 
then extracted via phenol-chloroform extraction and ethanol precipitation. 5’ linkers with 
a degenerate nucleotide end were ligated to the extracted RNA with T4 RNA ligase 
(Fermentas). The ligated reaction was then subjected to DNAse treatment with RQ1 
DNAse (Promega) and extracted with phenol-chloroform and ethanol precipitation, 
reverse transcribed with Superscript III (Invitrogen) and PCR amplified with Accuprime 
Pfx Supermix (Invitrogen) for 20-35 cycles. PCR products were run on a 10% denaturing 
polacrylamide gel and visualized with SYBR Gold (Molecular Probes). Products running 
between 60-100nt were excised from the lowest cycle number with visual product and gel 
extracted. Additional PCR amplification followed by gel extraction was performed with 
fusion primers as previously described to provide the platform for Illumina sequencing. 
10-30uL of 10nM DNA was submitted for sequencing on Illumina HiSeq. 
Processing and alignment of HITS-CLIP reads 
HITS-CLIP reads were filtered by quality (the first 5 nucleotides had a minimum 
quality score of 15 and the next 45 had a minimum mean score of 15) and exact 
sequences were collapsed. The 5’linker was stripped off and Illumina adapter sequences 
were clipped from the 3’ end (Fastx Toolkit). Reads were then parsed by size into mRNA 
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(≥25nt) and miRNA(≥17nt and ≤ 24nt) fractions. miRNA reads were aligned to mm9 
using bowtie (v0.12.8) with the following specifications: “-l 17 -v 2 --best --strata -m 
12”. To determine the best alignment strategy for his highly duplicated dataset we 
determined that the mmu-miRNAs mapped to a maximum of 12 separate genomic 
positions, so therefore we allowed up to 12 alignments per read. Read counts were 
quantified in SeqMonk (http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/) 
using miRNA intervals defined by miRBase (v18). miRNAs mapping to multiple 
positions in the genome were then collapsed. 
mRNA reads were uniquely aligned to mm9 using bowtie (v0.12.8) with the following 
options: “-v 2 --best --strata -m 1”. A second step of PCR duplicate removal was 
performed as previously described (9) in which reads with the same 5’ 5nt degenerate 
linker and the same coordinates were removed. This step eliminates true PCR duplicates, 
in which sequencing errors were also introduced, and would therefore be missed by an 
exact sequence collapser. Clusters made up of ≥8 reads and a 5nt overhang were 
identified. The peaks of the clusters were identified as previously described (8)  and the 
“Ago footprint” around the cluster broadly defined as the region 32nt upstream and 30nt 
downstream from the peak or narrowly defined as the region 22nt upstream and 24nt 
downstream of the edited say (region in which Ago is bound 100% of the time). The read 
depth of each footprint from HITS-CLIP and RNA-Seq was calculated using Seqmonk 
and CLIP depth was normalized to transcript expression (RNA-Seq read depth) to define 
the “Ago occupancy” (reads per million mapped CLIP/reads per million mapped RNA-
Seq). We find this method to be an accurate normalization, as it takes into account 
regions within each transcript that could be differentially expressed or differentially 
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mapped, a phenomenon neglected when normalizing to total transcript expression. Ago 
footprints were filtered to 17,477 that were contained within “expressed” regions, defined 
as an RPM of greater than or equal to 1, as this provided reasonable coverage of these 
regions, and would eliminate the any problems with artificially increasing Ago footprint 
occupancy values by normalizing to a value less than 1. The biological complexity (the 
number of replicates contributing to each Ago Footprint) was calculated based on the 
replicate contributing ≥2 reads to the footprint. “High-confidence” footprints (14,781) 
were defined as having a biological complexity of ≥2. As all APOBEC1 editing and most 
miRNA targeting happening within the 3′UTR of a given transcript, we narrowed our
search to only 3′UTRs. We generated a permissive 3′UTR database from RefSeq by
merging (with Bedtools) overlapping 3′UTR regions, thereby defining a region as a
3′UTR if it was catalogued as such in any transcript isoform. 6,270 “high-confidence”
footprints were contained within these merged 3′UTRs. Ago footprints were then
overlapped with APOBEC1 editing events to identify regions of potential 
Ago:APOBEC1 interaction. 
miRNA target search 
After the identification of high-confidence Ago footprints, we performed an 
exhaustive search to assign miRNA targets to those footprints and identify regions where 
APOBEC1 editing could create or destroy a miRNA target region. Using miRNA 
alignment data, we generated a list of bound miRNAs, defined as those that had a 
biological complexity of 3 in one of the two genotypes. Using a custom python script 
(available upon request) we scanned the footprint sequences for “canonical” matched 
miRNA 6mer seed regions (positions 2-7 of the mature miRNA sequence), as well as 
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other non-canonical matched 6mers from the 5’ end of the mature sequence (positions 1-
6 or 3-8). We also scanned the footprint sequences for “fuzzy” 6mers and 7mers (1 
nucleotide mismatch) and G-bulge seed regions (1 G insertion). Footprints were analyzed 
for the “best” miRNA target region fit, based on the sequence proximity to the footprint 
peak and the amount of the miRNA bound to Ago. We identified a number of target 
regions that were either created or destroyed by APOBEC1 editing events and tested 
these with standard luciferase reporter assays (described below). 
7.6. Luciferase Assays 
For miRNA dependent analysis: site-specific mutagenesis was performed on 
unedited (matched reference sequence) version target 3′UTRs and these were cloned into
luciferase vectors. Renilla luciferase served as an internal control. HEK293T cells were 
transfected with edited or unedited constructs plus the miRNAs of interest (synthesized 
by Dharmacon) using the DuoFECT reagent (and according to the manufacturer’s 
recommendations) or an unrelated microRNA control. Cells were returned to the 
incubator for 48 hours after which luciferase expression was assessed. Cells were lysed 
with passive lysis buffer by shaking at RT for 15min and subjected to one freeze-thaw 
cycle at -80°C. Firefly (experimental) and renilla (transfection control) luciferase 
expression were measured using the Dual-Luciferase reporter system (Promega) and a 
Fluostar Omega plate reader. Background luciferase levels (pmaxGFP) were subtracted 
from experimental samples. Firefly expression was normalized to Renilla (transfection 
control) for each construct.  We calculated the percentage of repression for both edited 
and unedited constructs using the reduction in luciferase activity induced by 
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overexpression of the microRNA of interest relative to the expression of the unrelated 
microRNA control (following the methods used by Loeb et al.127). The statistical 
significance for the differences was determined using a student’s T test with α= 0.05 
(Prism). The mRNA-miRNA pairs tested were Sptssa with miR17 (miR501 was used as 
unrelated control), Rac1 with miR669 (miR17 as control). 
For miRNA independent analysis: a series of edited and unedited 3′UTRs were
cloned using a high fidelity polymerase (Turbo, Invitrogen) from wildtype (“edited”) and 
Apobec1-/- (“unedited”) macrophage cDNA into a subclone vector (Strataclone). Clones 
were screened and representative clones for each degree of editing (single-site, number of 
hyper-edited events, etc.) were inserted downstream of a firefly luciferase in a dual-
luciferase vector (Promega). 
Apobec1-/- BMDMs were transfected with luciferase constructs and pmaxGFP 
transfection control vector using the Amaxa Mouse Macrophage Nucleofactor kit 
(Lonza). Cells were returned to the incubator for 24 hours after which luciferase 
expression was assessed. Cells were lysed and luciferase was determined as described in 
the previous section. In all cases, significance for the difference between each “edited” 
and “unedited” pair was calculated by a Mann-Whitney test (Prism). We tested a total of 
6 single-site edited transcripts (Cd36, Tmem55a, Sptssa, Sep15, Anxa5 and Rac1) and 
several combinations of editing in hyper-edited transcripts (B2m, App, Lamp1 and 
Adam10). 
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7.7. High-throughput Ribosome profiling 
Ribosome profiling libraries were prepared using the Truseq Ribo Profile kit per 
manufacturer’s instructions. Libraries were sequenced with 50 nt single end reads on the 
Illumina HiSeq 2500. Alignment, and mRNA and RPF read counting were performed as 
described in 20. Briefly, libraries were trimmed for adapters and quality using Trim 
Galore. The resulting reads were initially aligned to mouse ribosomal RNA using bowtie 
(v1.1.2). The remaining unmapped reads were then aligned to mm10 (using the reference 
sequences and annotations provided by iGenomes (Illumina)) using Tophat2 (v.2.1.0) and 
the following parameters: –bowtie1, –no- novel-juncs, –read-realign-edit-dist=0 (default 
settings for the remaining parameters). mRNA reads were counted using HTseq in 
intersection-strict mode, and RPF reads were counted using a custom script provided by 
Xiao et al87. DESeq2 was then used to assess changes in translational efficiency (TE), 
defined here as the ratio of RPF to mRNA reads, between the two genotypes. This was 
achieved with the design ~ assay + genotype + assay:genotype + batch, and analysis run 
as follows: dds <- DESeq(dds, test='LRT', full=design(dds), reduced = ~ assay + 
genotype + batch), where assay indicates if the library was mRNA or RPF, genotype 
indicates if the sample was WT or KO, and batch indicates the batch that the library was 
prepared with. Differential gene expression analysis was also performed, with DESeq2, 
using only the total mRNA reads generated from the Ribo-Seq experiment. 
7.8. Single cell RNA-Seq 
To generate single-cell libraries, wild-type bone marrow-derived macrophages 
were flowed into a C1 IFC for mRNA seq (10–17 mm) chip using the Fluigidm system. 
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Lysis, RT and PCR were performed using the SMARTer Kit designed for the C1 
(Clontech, Mountain View, CA). The efficiency of chip loading (capture) was confirmed 
by microscopy and any of the wells that contained either none or more than one cell were 
noted and discarded from further library preparation and analysis. In all, 24 single cDNA 
libraries were selected for library preparation on the basis of concentration and size 
range, as determined via Agilent Bioanalyzer. Sequencing libraries were made from the 
cDNA using the Nextera XT DNA Sample Preparation Kit (Illumina). To generate 
conventional bulk RNA-seq libraries, total RNA was extracted using Trizol (Invitrogen, 
Grand Island, NY) from 500,000 to 1,000,000 macrophages of each genotype (wild type 
and APOBEC1_/_). A unit of 1 mg of the total RNA collected per condition was then 
treated with DNase, and then processed using the NEBNext Ultra Directional RNA 
Library Prep Kit for Illumina (NEB, Ipswich, MA). 
Libraries were sequenced on the Illumina HiSeq 2000, generating 100-nucleotide, 
single-end reads. Reads were trimmed for quality and adapters using Trim Galore!, and 
then aligned to mm10 (using the reference sequences and annotations provided by 
iGenomes (Illumina)) using Tophat2, allowing only unique alignments and up to 2 
mismatches per 20-nucleotide segment. Gene expression was determined using 
Cufflinks32. The correlation of gene expression between the ensemble of single cells and 
the bulk was calculated using the Spearman and Pearson correlation coefficients. 
Potential PCR duplicates were removed from single cell alignments using Picard 
(http://broadinstitute.github.io/picard). 
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7.9. Hierarchical Statistical Model 
A lay summary of the method is described here; for full methods, including the 
mathematical derivation, please see Harjanto el at. 201680. First, an editable site of 
interest on a given RNA transcript and its associated probability of editing were selected. 
The transcript can be modeled as a coin with a probability of falling on ‘Heads’ when 
tossed equal to the associated editing probability (not necessarily 50%). We can think of 
each single cell as consisting of a stack of coins (with each coin corresponding to the 
same site on a different copy of the transcript), each having the same probability of 
falling on ‘Heads’. Finally, we can think of the population of cells as a bag full of stacks 
of coins, where the probability of ‘Heads’ for each stack is drawn from an unknown 
distribution on [0, 1]. The variance of this distribution quantifies the diversity among 
editing rates of different cells (or stacks of coins). The single-cell experiments correspond 
to randomly picking any number of stacks from the bag and tossing some of their coins, 
whereas the bulk experiment corresponds to randomly picking a large number of 
individual coins from the bag, after emptying all the stacks in and mixing them together. 
Because we assume that the edited sites can be treated independently, we can restrict 
attention to just a single genomic location, for which we can estimate a posterior 
distribution by applying Bayes’ rule and the appropriate Markov chain Monte Carlo 
algorithms. The posterior density of the variance provides a quantification of RNA 
editing variance. 
To test the model, we performed simulations using artificial data sets comprising 
of 20 cells exhibiting high levels of editing variance for a theoretical site, generated by 
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randomly sampling the number of edited reads to attain effective editing rates only in the 
region of 0-5% and 95-100%. 
7.10. Targeted single-cell RT–PCR 
To analyze editing of specific sites in single cells, single wild-type macrophages 
were sorted into 96-well PCR plates with 5-ml of lysis buffer, containing 0.45% NP-40, 
0.36Uml_1 RNAse Inhibitor and 0.18Uml_1 Superase-In (Ambion). RT–PCR 
amplification was done with gene specific primers and the OneStep RT–PCR kit 
(Qiagen), using a modified protocol. Single transcript molecules were tagged with 
barcoded gene-specific primers that have an additional universal sequence, used in RT. 
These primers were then digested with 1U of Exonuclease I (30 oC for 30 min; NEB). 
Afterwards, a mix of universal forward and gene specific reverse primers were added to 
the PCR mix and 35–40 cycles of PCR were performed. The PCR products were 
introduced into bacteria using a TOPO TA cloning kit (Invitrogen) and single bacterial 
colonies were sequenced using Sanger sequencing. The resulting sequences were then 
aligned to the reference transcriptome (Macvector) and PCR duplicates were eliminated 
using the barcodes. 
Transcript specific primer sequences were as follows: 
B2m primers: 
RT: 
 50-
GGCCAGTGAATTGTAATACGACTCACTATAGGNNNNNNAAAGCAGAAGTAG
CCACAGGGTTG-30 
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PCR-reverse: 50-TTAAGCATGCCAGTATGGCCGA-30 
Anxa5 primers: RT: 
 50-
GGCCAGTGAATTGTAATACGACTCACTATAGGNNNNNNGTCGCCAATGTTTT
GGAT ACTACCATC-30 
PCR-reverse: 50-GCGACACATCTGGAGACTATAA GAAGGC-30  
Cybb primers: RT: 
 50-
GGCCAGTGAATTGTAATACGACTCACTATAGGNNNNNNGAGGGTTTGTGCCT
AGTCTTATTGCA-30 
PCR-reverse: 50-GCATGCGCTCATCTTGTTTTGACTTC-30 
Universal PCR-forward: 50-GGCCAGTGAATTGTAATACGACTCACTATAGG-30 
7.11. Migration assay 
BMDMs from wildtype or Apobec1-/- mice were starved in serum free DMEM, 
containing 0.2% BSA and 20 ng/mL mCSF for twelve hours. The lower chambers of the 
96 well chemotaxis plate (Neuroprobe 8um, cat. 106-8) were filled with 30uL of DMEM 
0.2% BSA in the absence or presence of increasing concentrations of murine CXCL12 
(Peprotech), in triplicate. Macrophage suspensions (in phenol red free DMEM (Life 
Technologies) containing 0.2% BSA) were deposited on the top portion of the migration 
plate and placed at 37°C, 5% CO2, for 4 hours. Cells that did not migrate were aspirated 
off the top portion of the filter, which was also wiped with a cotton tip. BMDMs attached 
to the lower surface of the filter were centrifuged in a 96 well black plate with clear 
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bottom containing lysis buffer with CyQuant DNA-binding dye (Life Technologies). 
Fluorescence (excitation 485nm- emission 530nm) was measured using the Synergy Neo 
plate reader, after a 30-minute incubation at room temperature with gentle shaking. The 
chemotactic index was calculated by dividing the fluorescence intensity of each sample 
by the fluorescence intensity in the absence of chemokine. Data was analyzed using 
Prism 6.0g software (GraphPad Software, San Diego, CA) and statistical significance of 
the differences between the various conditions was determined using multiple measured 
one-way analysis of variance, with Bonferroni’s correction for the t test. 
 7.12. pHrodo assays 
Wildtype and Apobec1-/- BMDM were incubated with 1(MOI 10) or 10mL (MOI 
100) of pHrodo Red E. coli BioParticles (Invitrogen) in HBSS at 37C without CO2 FOR 
20 min. After the incubation period, cells were washed twice with HBSS and stained with 
Alexa 488 F4/80. Cells were detached with 5mM EDTA in PBS and analyzed via flow 
cytometry on a FACS Calibur flow cytometer. 
7.13 Bone marrow chimeras 
Bone marrow was collected from 8 Apobec1-/- CD45.2 and pooled; same with 8 
wildtype CD45.1 mice. Lineage positive cells were depleted using a cocktail of MAC1, 
GR-1, B220, CD4, CD8, CD3, Ter119, CD19, CD11c and NK1.1 biotinylated antibodies 
(BD Pharmingen) together with streptavidin columns (MACS). Wildtype CD45.1 mice 
(Jackson labs) or heterozygote for both CD45.1/CD45.1 and Apobec1+/- were lethally 
irradiated (with two doses of radiation delivered 3 hr apart and totaling 950 rad) and 
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injected (retro-orbitally) with a 1:1 mix of CD45.1 wildtype and CD45.2 Apobec1-/- 
lineage depleted cells. Spleens from chimeric mice were collected 28 days post-transplant 
in both backgrounds and 48 days in two mice transplanted in the CD45.1 background. 
For the analysis of macrophages in spleen, cells were stained with Ax488 F4/80, PerCP-
Cy5.5 CD11b, APC Ly6C, Aqua death cell exclusion, BV711 CD45.1, BUV395 CD45.2, 
PE Ly6G, PE-Cy7 CD11c. For the analysis of bone marrow, cells were stained with 
biotinylated CD3, CD19, NK1.1 and Ly6G; followed by staining with Ax488 CD115, 
PE-CF594 Streptavidin, PE CD135, BV421 CD117, Aqua dead cell exclusion, BV711 
CD45.1 and BUV395 CD45.2. T cells were identified as either CD3+CD4+ or 
CD3+CD8+, with FITC CD4, PE CD3, APC CD8, Aqua dead cell exclusion, BV711 
CD45.1 and BUV395 CD45.2. B cells in spleen were defined as CD19+B220+, stained 
with Ax488 B220, PE CD19, Aqua dead cell exclusion, BV711 CD45.1 and BUV 
CD45.2. In bone marrow, B cell progenitors were stained with Alexa 488 B220, PE 
CD43, PE-Cy7 IgM, Aqua dead cell exclusion, BV711 CD45.1, BUV395 CD45.2.  Pro-
B cells were defined as IgM-B220+CD45high, Large Pre-B cells as IgM-
B220+CD43medFSC-Ahigh, and Pre-B cells as IgM-B220+CD43medFSC-Alow.  The 
quantification of populations was done via flow cytometry using an LSR Fortessa (BD 
Biosciences) cell analyser. 
7.14. High throughput amplicon sequencing of edited fragments 
CD11c+ and CD11Cneg cells were isolated from cortex and hippocampus by 
MACS column separation. Briefly, cells were incubated with biotinylated CD11c 
antibodies (BD) and the CD11c+ fraction was retained in a MACS (Miltenyi Biotec). The 
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eluted cells were then incubated with a biotinylated CD11b antibody and the CD11c- (but 
CD11b+) fraction was retained in a separate MACS column. A 300bp fragment 
surrounding a predicted edited site was amplified from both CD11c+ and CD11c- cDNA 
and genomic DNA. Next, all the PCR products were purified and mixed. Library 
preparation was performed on the mixed sample using the Illumina True-seq kit and was 
sequenced in an Illumina mi-Seq. Reads were aligned to the genome and editing 
frequency was determined by counting the number of changes to the reference genome, 
using a custom script. 
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